WO2006027711A2 - Prodrugs and codrugs containing bio- cleavable disulfide linkers - Google Patents
Prodrugs and codrugs containing bio- cleavable disulfide linkers Download PDFInfo
- Publication number
- WO2006027711A2 WO2006027711A2 PCT/IB2005/052797 IB2005052797W WO2006027711A2 WO 2006027711 A2 WO2006027711 A2 WO 2006027711A2 IB 2005052797 W IB2005052797 W IB 2005052797W WO 2006027711 A2 WO2006027711 A2 WO 2006027711A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drugs
- mmol
- prodrug
- acid
- group
- Prior art date
Links
- 0 CC(CN(C*)C*)=O Chemical compound CC(CN(C*)C*)=O 0.000 description 27
- IRIXNPFNEAFXBV-UHFFFAOYSA-N CC(C)(C)OC(NCCSSCCOC(Cl)=O)=O Chemical compound CC(C)(C)OC(NCCSSCCOC(Cl)=O)=O IRIXNPFNEAFXBV-UHFFFAOYSA-N 0.000 description 1
- VCCDBBWDYAEKQE-UHFFFAOYSA-N CCCC(CCC)C(OCCSSCCNC(c1cccnc1)=O)=O Chemical compound CCCC(CCC)C(OCCSSCCNC(c1cccnc1)=O)=O VCCDBBWDYAEKQE-UHFFFAOYSA-N 0.000 description 1
- RDXYGIWINCDIQJ-JTQLQIEISA-N CC[C@@H](C(NC(OCCSSCCO[N+]([O-])=O)=O)=O)N(CCC1)C1=O Chemical compound CC[C@@H](C(NC(OCCSSCCO[N+]([O-])=O)=O)=O)N(CCC1)C1=O RDXYGIWINCDIQJ-JTQLQIEISA-N 0.000 description 1
- OPZCWTONCMEVJC-UHFFFAOYSA-N NC(C=CN1C2OC(COC(OCCSSCCO)=O)SC2)=NC1=O Chemical compound NC(C=CN1C2OC(COC(OCCSSCCO)=O)SC2)=NC1=O OPZCWTONCMEVJC-UHFFFAOYSA-N 0.000 description 1
- OAHFAPXIBISUJB-UHFFFAOYSA-N NCCSSCCO Chemical compound NCCSSCCO OAHFAPXIBISUJB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/91—Nitro radicals
Definitions
- the present invention relates to compositions of prodrugs, including NO-releasing prodrugs, codrugs, double prodrugs and mutual prodrugs, containing bio-labile linkers and linkages, processes for their preparation and pharmaceutical compositions containing them and their use.
- a prodrug is an active drug chemically transformed into a per se inactive derivative which by virtue of chemical or enzymatic attack is converted to the parent drug within the body before or after reaching the site of action.
- the process of converting an active drug into inactive form is called drug latentiation.
- Prodrugs can be carrier-linked- prodrugs and bioprecursors.
- the carrier-linked prodrug results from a temporary linkage of the active molecule with a transport moiety.
- Such prodrugs are less active or inactive compared to the parent active drug.
- the transport moiety will be chosen for its non- toxicity and its ability to ensure the release of the active principle with efficient kinetics.
- the bioprecursors result from a molecular modification of the active principle itself by generation of a new molecule that is capable of being a substrate to the metabolizing enzymes releasing the active principle as a metabolite.
- Prodrugs are prepared to alter the drug pharmacokinetics, improve stability and solubility, decrease toxicity, increase specificity, and increase duration of the pharmacological effect of the drug.
- By altering pharmacokinetics the drug bioavailability is increased by increasing absorption, distribution, biotransformation, and excretion of the drug.
- Limited intestinal absorption, distribution, fast metabolism, and toxicity are some of the causes of failure of drug candidates during development. Avoidance of the foreseeable or proven pharmacokinetic defects thus assumes considerable significance in drug research. Accordingly, prodrugs play a significant role in drug research as well.
- the linkage between the carrier and the drug is usually a covalent bond
- the prodrug is inactive or less active than the active principle
- the prodrug synthesis should not be expensive
- the prodrug has to be reversible or bioreversible derivative of the drug
- the carrier moiety must be non-toxic and inactive when released.
- Prodrugs are usually prepared by: a) formation of ester, hemiesters, carbonate esters, nitrate esters, amides, hydroxamic acids, carbamates, imines, mannich bases, and enamines of the active drug, b) functionalizing the drug with azo, glycoside, peptide, and ether functional groups, c) use of polymers, salts, complexes, phosphoramides, acetals, hemiacetals, and ketal forms of the drug. For example, see Andrejus Korolkovas's, "Essentials of Medicinal Chemistry", pp. 97-118.
- NO endothelium-derived nitric oxide
- NO is produced from arginine by the catalytic action of nitric oxide synthase. See, for example, Nathan, C. et al., Cell 1994, 78, 915, and Marietta, M. A., Cell 1994, 78, 927.
- NO is a free radical as well as a scavenger of free radicals. NO reacts quickly with ubiquitously generated reactive oxygen species (ROS) such as superoxide (O 2 " ) to generate a nefarious peroxynitrite (ONOO " ) molecule, which is implicated in many human diseases such as diabetes, heart disease, Alzheimer's disease and multiple sclerosis. In this setting, NO is often viewed as pathogenic. However, the chemistry of NO can also be a significant factor in lessening the injury mediated by reactive oxygen species (ROS) and reactive nitrogen oxide species (RNOS). There is a relationship between NO and oxidation, nitrosation and nitration reactions. A number of factors determine whether NO promotes, abates or interconnects these chemistries. See, for example, Espay, et al., A chemical perspective on the interplay between NO, reactive oxygen species, and reactive nitrogen oxide species, Ann N. Y. Acad. Sci. 2002, 962, 195.
- ROS reactive oxygen species
- NO is placed in a pivotal regulatory position. Insight into these pathophysiological processes and signaling are highly relevant to develop therapeutics.
- NO deficiency has been implicated in the genesis and evolution of several disease states.
- the production of superoxide is increased and level or location of NO synthesis is disrupted thereby causing cellular dysfunction as a result of vasoconstriction of blood vessels, which can lead to, if prolonged, cell damage or death.
- Agents that act to maintain the normal balance between NO and superoxide in vascular endothelial cells may prove particularly useful in this regard. See, for example, Stokes, K., et al., Free Radic. Bio. Med., 2002, 33, 1026-1036.
- Nutritional and pharmacological therapies that enhance the bioactivity or production of NO have been shown to improve endothelium-dependent vasodilation, reduce symptoms, and slow the progression of atherosclerosis.
- Some of the strategies for NO modulation encompass anti-inflammatory, sexual dysfunction, and cardiovascular indications.
- several commonly used cardiovascular drugs exert their beneficial action, at least in part, by modulating the NO pathway.
- Pharmacological compounds that release NO have been useful tools for evaluating the pivotal role of NO in cardiovascular physiology and therapeutics.
- NO-DONORS There are a wide variety of structurally dissimilar organic compounds that act as
- NO donors and release NO in solution Some NO donors, such as isoamyl nitrite, nitroglycerine (GTN) and sodium nitroprusside, have been used in cardiovascular medicine long before their biochemical mechanism was understood.
- GTN nitroglycerine
- the common mode of action for these drugs is liberation of NO, which evokes relaxation of smooth muscle through activation of guanylate cyclase with subsequent formation of cGMP.
- the relative importance of enzymatic versus non-enzymatic pathways for NO release, the identity of the actual NO-generating enzymes and the existence of competing metabolic events are additional important determinants of the different NO donor classes.
- Pharmacological compounds that release NO constitute two broad classes of compounds: those that release NO or one of its redox congeners spontaneously and those that require enzymatic metabolism to generate NO. See, for example, Ignarro, L. J. et al., Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview, Circ. Res. 2002, 90, 21-28.
- Nitroglycerine/glycerine trinitrate (GTN) and compounds referred to as nitrovasodilators or NO donors are frequently used in the treatment of ischemic heart disease.
- the common mode of action for these drugs is liberation of NO, which evokes relaxation of smooth muscle through activation of guanylate cyclase with subsequent formation of cGMP.
- GTN glycerine/glycerine trinitrate
- nitrate therapy particularly during acute myocardial infarction, has been the clinically significant drawback with GTN and some of the other available organic nitrates. This is a significant clinical problem and there exists a need for novel nitrate-based anti-anginal agents, which do not cause the problem of nitrate tolerance.
- Nicox's patents include: Synthesis and evaluation of nitrooxy derivatives of NSAIDs (WO 9412463, WO 0230867, WO 0292072, WO 0313499 and WO 0384550), aspirin (WO 9716405, WO 0044705 and WO 0104082), paracetamol (WO 0112584 and WO 0230866), antiepileptic agents (WO 0300642 and WO 0300643), COX-2 inhibitors (WO 0400781 and WO 0400300), statins (WO 04105754), ACE inhibitors (WO 04110432 and WO 04106300), and of known drugs used for the treatment of disease conditions resulting from oxidative stress and endothelial dysfunction (WO 0061537).
- nitrate esters were shown to possess not only superior or equal efficacy when compared to the original drug but also exhibit much-reduced side effects. In fact, because of their superior efficacy combined with reduced toxicity, a few of such nitrate ester-containing drug conjugates are successfully passing through various stages of clinical trials.
- Nicox's nitrooxy derivatives of drugs which are in clinical trials include: NCX 4016 (Phase II, peripheral vascular diseases), NCX 701 (Phase II, Acute pain), HCT 1026 (Phase I, Alzheimer's disease), HCT 3012 (Phase II, Osteoarthritis), NCX 285 (IND, Osteoarthritis), NCX 1022 (Phase Ha completed, Dermatitis), NCX 1020 (Phase I, Asthma/COPD), NCX 1000 (Phase I, Portal hypertension), and NCX 1510 (Phase II, Allergic rhinitis).
- NCX 4016 Phase II, peripheral vascular diseases
- NCX 701 Phase II, Acute pain
- HCT 1026 Phase I, Alzheimer's disease
- HCT 3012 Phase II, Osteoarthritis
- NCX 285 IND, Osteoarthritis
- NCX 1022 Phase Ha completed, Dermatitis
- NCX 1020 Phase I, Asthma/COP
- WO 9842661 has shown superior vasorelaxant activity and no tolerance was observed to the cGMP-increasing effects of those compounds under the same experimental conditions used for the induction of in vivo tolerance.
- WO 0149275 reports drug conjugates where an anti-inflammatory drug is covalently linked to the ⁇ et ⁇ -mercapto-nitrate via thioester bond. Biotransformation pathways proposed for NO release from GTN have largely been heme-dependent or sulfahydryl-dependent. See, for examples, Thatcher, G. R. J. et al., Chem.Soc. Rev. 1998, 27, 331 and reference cited therein, and Bennett, B M. et al., Trends Pharmacol, Sci.
- a mutual prodrug is the association in a unique molecule of two drugs, usually synergistic, attached to each other, one drug being the carrier for the other and vice versa.
- the embodiments of the invention also provide mutual prodrugs, which are prodrugs of two or three therapeutic agents currently used/potential for use in combination therapy utilizing novel bio-cleavable linkers, water-soluble prodrugs of insoluble/sparingly- soluble therapeutic agents using the same linker technology and water-soluble double and triple prodrugs of sparingly-soluble therapeutic agents or any of the prodrugs linked to NO-releasing agent using the same linker technology.
- a and A 1 independently represent a bond, (CH 2 )a, 1,2-phenylene, 1,3-phenylene or 1,4- phenylene; d is 1-8;
- D 1 represents a therapeutic agent comprising one or more of the functional groups selected from the group consisting of -OH, -SH, -NHR 1 , -CO 2 H, -CONHR 1 , - ⁇
- D 2 independently represents D 1 , a peptide, protein, monoclonal antibody, vitamin, R 2 , R 3 , R 4 , NO, NO 2 , a linkable nitric oxide-releasing group comprising a NONOate, a group comprising one or more of water-solubilizing functional groups, or a polymer;
- E independently represents CH 2 or a bond
- L 1 and L 2 independently represent a bond, O, S, NR 1 , L, or a linkage selected from the group consisting of:
- L is R 12 or a group with bonding in any direction, independently selected from the group consisting of:
- X independently represents a bond, C, O, S, or NR 1 ;
- Z independently represents a bond, or (CH 2 )J; wherein, j is 1-4;
- R 1 independently represents a bond, H, (C 1 -Cs)alkyl, (Cs-Cu)SIyI, aralkyl or M 6+ ;
- R 2 independently represents H, NH 2 , or NHAc;
- R 3 independently represents H, CO 2 R 5 , CH 2 CO 2 R 5 ,
- R 4 independently represents H, OH, 0-(Ci-C 8 )alkyl, 0M e+ , or a group selected from the group consisting of:
- X 2 independently represents O, S, SO, SO 2 , or NR 5 ;
- R 6 independently represents H, Na + , K + , any other pharmaceutically acceptable metal ion, (Ci-C 8 )alkyl, or (C 3 -C 8 )cycloalkyl,
- R 7 independently represents at each occurrence same or different R 5 ;
- R 9 independently represents H, (Ci-C 8 )alkyl or an amino acid; f is 0-6; g is 0-1; h is 1-2000; i is 1-4;
- R 10 and R 11 independently represent H, (Ci-C 8 )alkyl, (C 3 -C 8 )cycloalkyl, or a group selected from the group consisting of:
- R 11 represents H or (C 1 - C 8 )alkyl, and when R 11 is selected from the above group, R 10 represents H or (Ci- C 8 )alkyl;
- R 12 independently represents a group selected from the group consisting of:
- X 3 is independently O or NR 7 .
- Another embodiment of the invention is a pharmaceutical composition
- a pharmaceutical composition comprising one or more compounds of formula I or intermediates thereof and one more of pharmaceutically acceptable carriers, vehicles or diluents.
- Further embodiments include methods of preparation and methods of use of prodrugs including NO-releasing prodrugs, double prodrugs and mutual prodrugs comprising the compounds of formula I.
- the present invention characterizes compositions, methods of preparation and methods of use of prodrugs, NO-releasing prodrugs, mutual prodrugs, double prodrugs, and codrugs.
- the compounds of the present invention are prodrugs or mutual prodrugs in which known therapeutic agents or potential therapeutic agents are linked covalently to novel biocleavable linkers.
- the compounds of the present invention also include NO-releasing prodrugs in which a therapeutic agent is linked covalently to nitrooxy (nitrate ester) group via a novel bio-cleavable linker containing a strategically placed disulfide group at ⁇ -position to the nitrate ester.
- the present invention also characterizes composition of NO-releasing prodrugs (i.e., nitrooxy ester or nitrate ester prodrugs), processes for their preparation, pharmaceutical composition containing them and their use.
- amino-containing refers to drug/carrier molecule with NH functional groups such as amino (both primary and secondary), amide, urea, sulfonamide, carbamate, phosphoramadite, sulfamate, hydrazone, semicarbazone, thiosemicarbazone, hydrazide, carbazate and the like.
- This also includes NH-containing heterocylic compounds such as imidazoles, benzimidazoles, pyrazoles, benzpyrazols, pyrrols, indoles, triazoles, tetrazoles, benzotriazoles, benzotetrazoles and their derivatives.
- NH-containing heterocyclic compounds can be sub-structures of more complex drug/carrier molecules.
- Amino group of the candidate drug can be primary or secondary (both acyclic and cyclic) which include amide-NH, sulfonamide-NH, carbamate-NH, sulfamate-NH, hydrazide-NH, hydrazone-NH, semicarbazone-NH, thiosemicarbazone- NH, urea-NH and also drugs containing indole, imidazole, benzimidazole, thiazole, oxozole, pyrrole, pyrazole, triazole, tetrazole, or similar NH-containing heterocylic sub ⁇ structures of a more complex drug molecule.
- hydroxyl-containing refers to drug/carrier molecules with hydroxyl groups (primary, secondary and tertiary) including hydroxyl groups of hydroxamic acids and ketoximes derived from keto-containing molecules. Hydroxyl group of drugs can be of primary, secondary or tertiary nature.
- sulfahydryl-containing refers to drug/carrier with free sulfahydryl (SH) group.
- halo refers to fluoro, chloro, bromo, and iodo.
- halide refers to fluoride, chloride, bromide, and iodide.
- alkyl refers to acyclic alkyl chains.
- C 1 -C 8 alkyl refers to methyl, ethyl, propyl, isopropyl, butyl, cyclobutyl, s-butyl, and t-butyl, ,pentyl, hexyl, heptyl, octyl, and the like.
- cycloalkyl refers to cyclic alkyl chains, e.g., the term “C 3 -C 8 cycloalkyl” refers to cyclopropyl, cyclooctyl, cyclopentyl, cyclohexyl, cycloheptyl, , cyclooctyl and the like.
- aryl refers to phenyl, naphthyl and the like.
- aralkyl refers to benzyl, phenethyl and the like.
- alkoxy refers to both acyclic and cyclic Ci-C 8 alkyloxy.
- Ci-C 8 alkyloxy refers to methoxy, ethoxy, propoxy, isopropoxy, cyclopropoxy, butoxy, cyclobutoxy, s-butoxy, and t-butoxy, cyclopentyloxy, pentyloxy, hexyloxy, cyclohexyloxy, heptyloxy, cycloheptyloxy, octyloxy, cyclooctyloxy and the like.
- heterocyclic and heteroaryl refers to both saturated and unsaturated 5- and 6-membered rings (including benzo-fused) containing from 1 to 4 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. All of these rings may be substituted with up to three substituents independently selected from the group consisting of amino, halo, alkoxy, alkyl, cyano, nitro, hydroxyl, sulfahydryl, carboxyl and the like, Saturated rings include, for example, pyrrolidinyl, piperidinyl, piperazinyl, tetrahydrofiiryl, oxazolidinyl, dioxanyl, pyranyl, and the like.
- Benzofused saturated rings include indolinyl, 1,2,3,4-tetrahydroquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl and the like.
- Unsaturated rings include furyl, thienyl, pyridinyl, pyrrolyl, N-methylpyrrolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, tetrazolyl, triazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, pyrimidinyl, pyrazinyl, pyridazinyl, and the like.
- Benzofused unsaturated rings include isoquinolinyl, benzoxazolyl, benzthiazolyl, quinolinyl, benzofuranyl, thionaphthyl, indolyl and the like.
- substituted alkyl refers to acylic and cyclic alkyl groups substituted with one or more of groups such as alkyl, aryl, hydroxy, alkoxy, cyano, carboxyl, sulfahydryl, alkylthio, amino, nitro, halo, carbonyl, carbamato, sulfamato, sulfonato, sulfato, and the like.
- substituted aryl refers to aryl groups substituted (including fused) with one or more of groups such as alkyl, aryl, hydroxy, alkoxy, cyano, carboxyl, sulfahydryl, .alkylthio, amino, nitro, halo, carbonyl, carbamato, sulfamato, sulfonato, sulfato, and the like.
- amino acid refers to molecules containing one or more amino and carboxyl groups.
- alfa-amino acids D-, L- and DL- amino acids
- alfa-amino acids include natural alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine.
- beta-amino acids and known unnatural amino acids.
- amino acid ester refers to an amino acid where the carboxyl group is substituted with a Ci-C 8 alkyl group. That is, the alkyl group when taken together with the carboxyl group forms a Ci -C 6 alkyl ester. It is appreciated that some amino acids (e.g., aspartic acid and glutamic acid) have two carboxyl groups these may form mono- and di-esters.
- protecting group refers to an 'amino protecting group' or a 'hydroxyl protecting group' or a 'carboxyl protecting group' and the like.
- amino protecting group refers to a group that selectively blocks or protects the amino functionality in presence of other functional groups on the molecule.
- amino-protecting groups examples include the formyl group, the trityl group, the phthalimido group, the acetyl group, the trifluoroacetyl group, the chloroacetyl, bromoacetyl, and iodoacetyl groups, urethane-type blocking groups such as benzyloxycarbonyl ("CBZ”), 9-fluorenylmethoxycarbonyl ("FMOC”), tert- butoxycarbonyl (“BOC”), trichloroethylcarbonyl and the like. Additional examples of amino protecting groups are described by T. W.
- Molecules with two or more amino groups may form mono-, di-, tri-, poly-, protected derivatives depending on the reaction conditions used.
- hydroxyl protecting group refers to a group that selectively blocks or protects hydroxyl functionality in presence of other reactive functional groups on the molecule.
- hydroxyl-protecting groups include, for example, ether groups including methyl and substituted methyl ether groups such as methyl ether, methoxymethyl ether, methylthiomethyl ether, tert-buylthiomethyl ether, triphenylmethyl, tetrahydropuranyl (THP), (phenyldimethylsilyl)methoxy-methyl ether, benzyloxymethyl ether, p-methoxybenzyloxy-methyl ether, and tert-butoxymethyl ether; substituted ethyl ether groups such as ethoxyethyl ether, l-(2-chloroethoxy)-ethyl ether, 2,2,2-trichloroethoxymethyl ether, and 2-(trimethylsilyl)ethyl ether; isopropyl ether groups;
- hydroxyl protecting groups are described by T. W. Greene, "Protective Groups in Organic Synthesis", John Wiley and Sons, New York, N.Y., 1991. Molecules with two or more hydroxyl groups may form mono- and di-esters/ethers depending on the reaction condition.
- carboxyl protecting group refers to a group that selectively blocks or protects carboxyl functionality in presence of other reactive functional groups on the molecule.
- carboxyl-protecting groups include, for example (substituted) alkyl esters such methyl ester, ethyl ester, t-butyl ester, (substituted) benzyl ester, trichloroethyl ester, and the like. Additional examples of carboxylic acid protecting groups are described T. W. Greene, "Protective Groups in Organic Synthesis", John Wiley and Sons, New York, N.Y., 1991. Molecules with two or more carboxylic acid groups may form mono-, di-, tri-, tetra-, poly- protected derivatives depending upon the reaction conditions used.
- carbonyl activating group refers to leaving group ("LG") of a carboxyl derivative that is easily replaced by an incoming nucleophile.
- LG leaving group
- Such “LG” groups include, but are not limited to, (substituted) alkoxy, aryloxy, nitrogen containing unsaturated heterocycles such as N-oxybenzotriazole, imidazolyl, o/p-nitrophenoxy, pentachloro- phenoxy, N-oxysuccinimide, N,N'-dicyclohexylisoure-O-yl, N-hydroxy-N- methoxyamino, and the like; acetates, formates, sulfonates such as methanesulfonate, ethanesulfonate, benzenesulfonate, or p-toluenesulfonate, and the like; and halides especially fluoride, chloride, bromide, or iodide.
- carbonyl activating reagent refers to a reagent that converts the carbonyl of a carboxylic acid group into one that is more susceptible to nucleophilic attack and includes, but is not limited to, such reagents as those found in "The Peptides”, Gross and Meienhofer, Eds., Academic Press (1979), Ch. 2, and M. Bodanszky, "Principles of Peptide Synthesis", 2.sup.nd Ed., Springer- Verlag Berlin Heidelberg, 1993, hereafter referred to as "The Peptides” and “Peptide Synthesis” respectively.
- Carbonyl group (i.e., aldehyde or keto group) of candidate drugs may be converted first to aldoxime, ketoxime, hydrazone, semicarbazone and the like, before coupling to the linker.
- carbonyl activating reagents include thionyl bromide, thionyl chloride, oxalyl chloride, and the like; esters of alcohols such as nitrophenol, pentachlorophenol, and the like; and compounds such as l,l'-carbonyldiimidazole (CDI), benzotriazole, imidazole, N-hydroxysuccinimide, dicyclohexylcarbodiimide (DCC), EDC, phosgene or its equivalents, N, N-dimethylaminopyridine (DMAP) and the like.
- CDI l,l'-carbonyldiimidazole
- DCC dicyclohexylcarbodiimide
- EDC phos
- phosgene or its equivalents refer to phosgene or it equivalents such as diphosgene, triphosgene, CDI, DSC, BTBC, alkoxycarbonyl chlorides, o/p- nitrosubstituted phenoxycarbonyl chlorides, and the like.
- pharmaceutical when used as an adjective means substantially non-toxic to living organisms.
- salts refer to salts of the compounds of this invention, which are substantially non-toxic to living organisms. See, e.g., Berge, S. M. et al., "Pharmaceutical Salts", J. Pharm. Sci., 66:1, 1977.
- Typical pharmaceutical salts include those salts prepared by reaction of the compounds of this invention with an inorganic or organic acid or base. Such salts are known as acid addition or base addition salts respectively.
- These pharmaceutical salts frequently have enhanced solubility characteristics compared to the compound from which they are derived, and thus are often more amenable to formulation as liquids or emulsions.
- Examples of pharmaceutically acceptable salts are those with inorganic bases such as sodium, potassium, calcium, magnesium, and hydroxides, and the like, or with organic bases such as lysine, arginine, triethylamine, dibenzylamine, piperidine, and the like.
- suitable solvent refers to a solvent that is inert to the ongoing reaction and sufficiently solubilizes the reactants to effect the desired reaction.
- suitable solvents include but are not limited to, dichloromethane, chloroform, 1,2- dichloroethane, diethyl ether, tert-butylmethyl ether, acetonitrile, ethyl acetate, 1,3- dimethyl-2-imidazolidinone, tetrahydrofuran, dimethylformamide, benzene, toluene, xylene, N-dimethylacetamide, N-methylpyrrolidine, chlorobenzene, dimethylsulfoxide, dimethoxyethane, water, methanol, ethanol, isopropanol, pyridine, nitromethane, mixtures thereof, and the like.
- suitable base refers to a base, which acts as a proton trap for any protons, which may be produced as a byproduct of the desired reaction, or to a base, which provides a reversible deprotonation of an acidic proton from the substrate and is reactive enough to effect the desired reaction without significantly effecting any undesired reactions.
- bases include, but are not limited to, carbonates, bicarbonates, and hydroxides (e.g., lithium, sodium, potassium, magnesium, calcium and the like), sodium/potassium/calcium hydride, sodium/potassium alkoxide (i.e., methoxide, ethoxide, tert-butoxide and the like), triethylamine, diisopropylethylamine, N- methylpyrrolidine, N-methylmorpholine, tetramethylguinidine, or aromatic nitrogen containing heterocycles such pyridine, 4-(dimethylamino)pyridine (DMAP), and the like.
- carbonates bicarbonates, and hydroxides
- sodium/potassium/calcium hydride sodium/potassium alkoxide (i.e., methoxide, ethoxide, tert-butoxide and the like)
- sodium/potassium alkoxide i.e., methoxide, ethoxide, tert
- NONOate refers to a linkable nitric oxide-releasing group such as AcOCH 2 -O-N 2 -N(OOR 7 , OCHOCH 2 -O-N 2 -N(O " ) R 7 R 7 , CH 2 -O-N 2 -N(OOR 7 R 7 and the like.
- therapeutic agent refers to biologically active molecules such as drugs, vitamins, and other molecules, agents or substances concerned with or contributing to the treatment and cure of illness or contributing to the general well being of a mammal or human.
- the therapeutic agents can be both known and investigational drugs compiled in drug databases such as the Merck Index, IDdb, Prous Science's Integrity ® , Prous Science Drugs of the FutureTM, The Ensemble ® and the like.
- the Merck Index is a one-volume encyclopedia of chemicals, drugs and biologicals that contains more than 10,000 monographs. Each monograph in this authoritative reference source is a concise description of a single substance or a small group of closely related compounds.
- Prous Science is an international health science publishing company, established in 1958 and headquartered in Barcelona, Spain.
- Prous Science Drugs of the FutureTM contains comprehensive drug monographs providing product information on new compounds, including the synthesis and corresponding schemes, pharmacological action, pharmacokinetics and metabolism, toxicity, clinical studies, manufacturer, and references. Information on compounds is continuously updated as advances in development status are disclosed worldwide.
- the Prous Science IntegrityTM is a drug R&D portal where knowledge areas are coordinated to provide a harmonious and interrelated whole, which includes Drugs & Biologies, Targets, Organic Synthesis, Experimental Pharmacology, Pharmacokinetics and Metabolism, Clinical Studies, Disease Briefings, Companies & Markets, Literature and Patents.
- the Investigational Drugs database (IDdb) developed by Thomson Current Drugs, is a pharmaceutical competitor intelligence service. It covers all aspects of investigational drug development, from first patent to eventual launch or discontinuation.
- the Ensemble® on the Web provides essential information, including chemical structures, on more than 140,000 compounds with demonstrated biological activity in the drag research and development pipeline.
- vitamin includes vitamin A, vitamin C, thiamine, folic acid, biotin, inositol, nicotinic acid, nicotinamide, riboflavin, pyridoxine, pyridoxal 5-phosphate, ergosterol, vitamin D2, vitamin D3, vitamin D4, vitamin E, menadoxime, menadiol, and vitamin K5.
- peptide includes large and small peptides, including, but not limited to, targetable small peptides such as a dipeptide, tripeptide, tetrapeptide, etc.
- ligand means a small molecule that binds to a larger macromolecule, whether or not the ligand actually binds at a metal site. Such ligands can be small peptides.
- One aspect of the invention is to provide mutual prodrugs of two or three therapeutic agents currently used for use in combination therapy utilizing novel bio- cleavable linkers, water-soluble prodrugs of insoluble and sparingly-soluble therapeutic agents using the same linker technology, and water-soluble double and triple prodrugs of sparingly-soluble therapeutic agents using the same linker technology.
- the embodiments of the invention may also comprise vitamins and targetable small peptides in addition to or in place of a promoeity to yield targetable prodrugs.
- the candidate drugs selected for mutual prodrug synthesis can be from one therapeutic category or from different therapeutic categories.
- the constituent drugs of a mutual prodrug can act on the same biological target with similar mechanism of action or act on different biological targets with different mechanisms of action.
- the candidate drugs should contain one or more of the essential functional groups such as amino, hydroxyl, keto, or carboxyl groups in their structure.
- Amino group of the candidate drug can be primary or secondary (both acyclic and cyclic) which include amide-NH, sulfonamide-NH, carbamate-NH, sulfamate-NH, hydrazone-NH, semicarbazone-NH, thiosemicarbazone-NH and also drags containing indole, imidazole, benzimidazole, thiazole, oxozole, pyrrole, pyrazole, triazole, tetrazole, or similar NH-containing heterocylic sub-structures of a more complex drag molecule.
- hydroxyl group of drags can be of primary, secondary or tertiary nature.
- Keto group of candidate drugs may be converted first to ketoxime, hydrazone, semicarbazone and then like, before coupling to the linker. Obviously, hydroxyl or amino functions thus generated will be used to form covalent bond between the drug and the linker.
- the candidates for making mutual prodrugs can be the pairs of drugs that are currently used in combination therapy (including those combination studies at investigational stage) in various therapeutic areas provided each of those drugs possesses the requisite functional group(s). There are a number of therapeutic areas where such combination therapy is applied routinely and successfully.
- the disulfide bond in the prodrug is expected to be reduced by endogenous sulfahydryl-containing species such as glutathione (GSH) to generate a reactive thiolate anion (i.e., ⁇ eto-mercapto-nitrate), which can trigger further break-down of the linker moiety to release the free drug (via a mechanism as shown Scheme Ml) and NO simultaneously at the same location.
- GSH glutathione
- Scheme Ml reactive thiolate anion
- the release of NO can go via a hypothetical cyclic transient intermediate 'b'.
- sulfahydryl-dependent NO release from GTN Similar hypothetical mechanism was proposed for NO release from SS-nitrates, which, were also designed on the basis of a sulfahydryl-dependent NO release from GTN. See, for example, Zavorin, S. I. et al., Organic Letters, 2001, 3, 1113, incorporated herein in its entirety .
- Mutual prodrugs can be made by linking covalently any two of the following: an amino-containing therapeutic agent to another ammo-containing therapeutic agent; an amino-containing therapeutic agent to a hydroxyl-containing therapeutic agent; an amino- containing therapeutic agent to a carboxyl-containing therapeutic agent and its derivative; a hydroxyl-containing therapeutic agent to a carboxyl-containing therapeutic agent and its derivative; an amino-containing therapeutic agent to a carboxyl-containing therapeutic agent and its derivative; an amino-containing therapeutic agent to a keto-containing therapeutic agent or its hydazone, semicarbazone or oxime derivative and the likes;
- Another aspect of the present invention is to provide new nitrate ester (NO- releasing) prodrugs of many types of existing drugs using novel biocleavable likers. Such prodrugs are expected to exhibit better efficacy and tolerability with reduced side effects compared to the corresponding original drugs.
- An embodiment of present invention relates to the compounds of formula (I) or pharmaceutically acceptable salts thereof:
- a and A 1 independently represent a bond, (CH 2 )d, 1 ,2-phenylene, 1,3-phenylene or 1,4- phenylene; d is 1-8;
- D represents a therapeutic agent comprising one or more of the functional groups selected from the group consisting of -OH, -SH, -NHR 1 , -CO 2 H, -CONHR 1 , -
- D 2 independently represents D ⁇ a peptide, protein, monoclonal antibody, vitamin, R 2 , R 3 ,
- R 4 NO, NO 2 , a linkable nitric oxide-releasing group comprising a NONOate, a group comprising one or more of water-solubilizing functional groups, or a polymer;
- E independently represents CH 2 or a bond
- L 1 and L 2 independently represent a bond, O, S, NR 1 , L, or a linkage selected from the group consisting of:
- L is R 12 or a group with bonding in any direction, independently selected from the group consisting of:
- X independently represents a bond, C, O, S, or NR 1 ;
- Z independently represents a bond, or (CH 2 )J; wherein, j is 1-4;
- R 1 independently represents a bond, H, (Ci-C 8 )alkyl, (C 5 -Ci 4 )aryl, aralkyl or M 6+ ;
- R 2 independently represents H, NH 2 , or NHAc;
- R 3 independently represents H, CO 2 R 5 , CH 2 CO 2 R 5 ,
- R 4 independently represents H, OH, O-(Ci-Cs)alkyl, OM 6+ , or a group selected from the group consisting of: or arabinolactan,
- X 2 independently represents O, S, SO, SO 2 , or NR 5 ;
- R 6 independently represents H, Na + , K + , any other pharmaceutically acceptable metal ion, (Ci-C 8 )alkyl, or (C 3 -C 8 )cycloalkyl,
- R 7 independently represents at each occurrence same or different R 5 ;
- R 9 independently represents H, (Ci-C 8 )alkyl or an amino acid; f is 0-6; g is 0-1; h is 1-2000; i is 1-4;
- R 10 and R 11 independently represent H, (Ci-C 8 )alkyl, (C 3 -C 8 )cycloalkyl, or a group selected from the group consisting of:
- R 11 represents H or (Ci- C 8 )alkyl, and when R 11 is selected from the above group, R 10 represents H or (Q- C 8 )alkyl;
- R 12 independently represents a group selected from the group consisting of:
- X 3 is independently O or NR 7 .
- D 1 and D 2 of the present invention can be both known and investigational drugs compiled in drug databases such as the Merck Index, IDdb, Prous Science's Integrity ® , Prous Science Drugs of the FutureTM, The Ensemble ® and the like.
- D 1 and D 2 are the same drugs.
- D 1 and D 2 are different drugs.
- Dl is a drug and D -.2 may not be a drug at all.
- D 2 is an amino-, carboxyl- or hydroxyl- containing group or molecule comprising one or more water solubilizing functional groups selected from the group consisting of hydroxyl, amino, acylamino, carboxyl, sulphate, sulfonate, phosphate, phosphonate, N- acylsulfonamide, N-acylsulfamate, N-acylcarbamate, N-acylcarbamate metallic salts, and amino acids to give water-soluble prodrug.
- D 2 is an amino-, carboxyl- or hydroxyl- containing group or molecule comprising one or more water solubilizing functional groups selected from the group consisting of hydroxyl, amino, acylamino, carboxyl, sulphate, sulfonate, phosphate, phosphonate, N- acylsulfonamide, N-acylsulfamate, N-acylcarbamate, N-acylcarbamate metallic salts, and amino acids to
- Another embodiment of the invention is the compound of formula I, wherein D 2 is selected from the group of D, L and DL amino acids consisting of Alanine, Arginine,
- D 2 represents a polymer selected from the group consisting of arabinogalactan, polyamino acids, polyethylene glycol, polycaprolactone, polyglycolic acid, polylactic acid, polyacrylic acid, poly(2-hydroxyethyl 1 -glutamine), dextran and modified dextrans such as dextran aldehyde, carboxymethyl dextran, arabinogalactane aldehyde, carboxymethyl arabinogalactane, and hyaluronic acid.
- D 2 represents a polymer selected from the group consisting of arabinogalactan, polyamino acids, polyethylene glycol, polycaprolactone, polyglycolic acid, polylactic acid, polyacrylic acid, poly(2-hydroxyethyl 1 -glutamine), dextran and modified dextrans such as dextran aldehyde, carboxymethyl dextran, arabinogalactane aldehyde, carboxymethyl arabinogalactane, and hyal
- D 2 is a polyaminoacid selected from group consisting of poly(l-glutamic acid), poly(d- glutamic acid), poly(dl-glutamic acid), poly(l-aspartic acid), poly(d-aspartic acid), poly(dl- aspartic acid), copolymers of the polyaminoacids and polyethylene glycol,
- D 2 is a peptide, protein or monoclonal antibody for achieving targeted delivery of prodrugs and drugs.
- Another embodiment of the invention is the compound of formula I, wherein D 2 is a ligand or dipeptide or a dipeptide ligand.
- D 2 is a dipeptide ligand that is a substrate for intestinal transporters for selective intestinal absorption of the corresponding prodrugs thereby increasing the bioavailability of the prodrugs.
- D 2 is a targetable small peptide, i.e., dipeptide, tripeptide, tetrapeptide, etc.
- Another embodiment of the invention is the compound of formula I, wherein D 2 is a vitamin.
- Such vitamin-conjugated prodrugs are expected to be taken up by the diseased cells via receptor-mediated endocytosis.
- D 2 is selected from the group of vitamins consisting of vitamin A, vitamin C, thiamine, folic acid, biotin, inositol, nicotinic acid, nicotinamide, riboflavin, pyridoxine, pyridoxal 5-phosphate, ergosterol, vitamin D2, vitamin D3, vitamin D4, vitamin E, menadoxime, menadiol, and vitamin K5.
- Another embodiment of the invention is the compound of formula I, wherein D 1 and D 2 represent the same therapeutic agent to give a symmetrical double prodrug. Another embodiment of the invention is the compound of formula I, wherein D and D 2 represent different therapeutic agents to give a mutual prodrug. Another embodiment of the invention is the compound of formula (I), wherein D 1 and D 2 can be either from same or different therapeutic class. Another embodiment of the invention is the compound of formula (I), wherein D 1 and D 2 can be same or different therapeutic agents. Such therapeutic agents may have same or different mechanisms of action or they may work on different biological targets or work on different disease conditions.
- Another embodiment of the invention is the compound of formula I, wherein D 2 is R 2 , R 3 or R 4 .
- a further embodiment of the invention is the compound of formula I, wherein B is S-S, A and A 1 are CH 2 -CH 2 , E is a bond and D 2 is R 2 , R 3 or R 4 .
- Another embodiment of the invention is the compound of formula I, wherein a is 0; B is S-S; A and A 1 are CH 2 -CH 2 , E is a bond and D 2 is R 4 .
- Another embodiment of the invention is the compound of formula I, wherein a is 0; B is S-S; A and A 1 are CH 2 -CH 2 , E is a bond and D 2 is R 4 .
- Another embodiment of the invention is the compound of formula I, wherein a is
- B is a bond, (CH 2 )b, or (CH 2 CH 2 O) 0 ; wherein b and c are as defined above.
- Another embodiment of the invention is the compound of formula I, wherein a is 0, B is a bond, (CH 2 ) b or (CH 2 CH 2 O) 0 and D 2 is R 2 or R 3 or R 4 ; wherein b and c are as defined above.
- a and A 1 are CH 2 -CH 2, and E is a bond.
- a and A 1 are 1, 2-phenylene, 1,
- a and A 1 are CH 2 -CH 2, and E is a bond.
- a and A 1 are 1, 2-phenylene, 1, 3-phenylene or 1, 4-phenylene, and E is CH 2 .
- Another embodiment of the invention is the compound of formula I, wherein a is O; B is S-S; A and A 1 are 1, 2-phenylene, 1, 3-phenylene or 1, 4-phenylene; E is CH 2 and D 2 is D 1 Or R 2 or R 3 or R 4 .
- a further embodiment of the invention is the compound of formula I, wherein B is S-S, A and A 1 are CH 2 -CH 2 , E is a bond and D 2 is D 1 .
- Yet another embodiment of the invention is the compound of formula I, wherein a is O; B is S-S; A and A 1 are CH 2 -CH 2 , E is a bond and D 2 is a dipeptide ligand.
- the peptide ligands used in the invention can be substrates for intestinal transporters for selective intestinal absorption of the corresponding prodrugs thereby increasing the bioavailability of the prodrugs.
- An embodiment of the present invention is the compounds of formula (I), wherein D 1 , L 1 and L 2 are as defined above; A and A 1 are CH 2 ; E is CH 2 ; B is a bond or (CH 2 ) b ; b is 1-6; a is O; and D 2 is D 1 or R 2 or R 4 .
- Another embodiment of the present invention is the compound of formula (I), L 2 is O; A and A 1 are independently (CH 2 )a, 1,2-phenylene, 1,3-phenylene, or 1,4- phenylene; d is 1-4; B is S-S; a is 0; D 2 is NO 2 . In a further embodiment, when A and A 1 are independently (CH 2 )a, 1,2-phenylene, 1,3-phenylene, or 1,4- phenylene; d is 1-4; B is S-S; a is 0; D 2 is NO 2 . In a further embodiment, when A and A 1
- E is a bond.
- a and A 1 are independently 1,2-phenylene, 1,3-phenylene, or 1,4-phenylene.
- An embodiment of the present invention is the compound of formula (I), wherein D 1 is a hydroxyl or sulfahydryl containing drug molecule such as Drug-OH or Drug-SH, wherein functional groups OH and SH are involved in the formation of L 1 linkages between the drug and the linker; L 2 is O; E is bond, L 1 is a linkage selected from the group consisting of:
- An embodiment of the present invention is the compound of formula (I), wherein D 1 is a drug molecule having carboxyl (-CO 2 H) as a reactive functional group such as - CO 2 H which is involved in the formation of L 1 linkages between the drug and the linker; L 2 is O; E is bond; L 1 is O or NR 1 or a linkage selected from the group consisting of:
- D 1 is an antioxidant or free radical scavenger such as a hydroxyl-containing stable radical such a 4-hydroxy-2,2,6,6-tetramethylpiperidin-l-oxyl (4-hydroxy- TEMPO), 4-carboxy -2,2,6,6-tetramethylpiperidin-l-oxyl (4-carboxy-TEMPO) or any other ammo-/carboxyl-/hydroxyl-containing antioxidants or radical/super oxide scavengers, and D 2 is NO 2 .
- the amino-/carboxyl-/hydroxyl-containing antioxidants and radical/super oxide scavengers can be known or investigational.
- An embodiment of the present invention is the compound of formula (I), wherein
- L 1 is x X or ; wherein, X is a bond, O, S or NR 1 ; L 2 is O, E is a bond; A and A 1 are CH 2 CH 2 ; B is S-S; a is O; and D 2 is NO 2 .
- An embodiment of the present invention is the compounds of formula (I), wherein D ! and L 1 are as defined above; L 2 is O; A is 1,2-phenylene, 1,3-phenylene, or 1,4- phenylene; A 1 is CH 2 ; E is CH 2 ; B is S-S; a is 0 and D 2 is NO 2 .
- An embodiment of the present invention is the compounds of formula (I), wherein L 2 is O; A and A 1 are CH 2 ; E is CH 2 ; B is a bond or (CH 2 ) b ; b is 1-6; a is O; D 2 is NO 2 and L 1 is a group selected from
- X is O, S or NR 1 ; Rl is as defined.
- An embodiment of the invention is the compound of formula I selected from the groups consisting of: A. Prodrugs: (a) From carboxyl-containing drugs:
- R y1 An amino-, hydroxyl-containing molecule with water-solubilizing groups
- R 2 H, a bond, CH 2 CH 2 N(CH 3 ) 2 .
- HCl an Amino acid, or any molecule containing solubilizing groups such as carboxylic acid, sulphonic acid, hydroxyl, amino groups, polyethyleneglycol (PEG), a metal ion such a Na + , Ca 2+ , etc.
- PEG polyethyleneglycol
- An embodiment of the invention is a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective amount of the compound of formula I, or a pharmaceutical salt thereof and one or more pharmaceutically acceptable carriers, vehicles or diluents.
- Another embodiment of the invention is a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective amount of the compound of formula I selected from the group consisting of I-C1-PD1, 1-C1-PD2, 1-C1-PD3, 1-C1-PD4, 1-Cl-PD4a, I- Cl-PD4b, I-C1-PD5, 1-C1-PD6, 1-C1-PD7, 1-C1-PD8, 1-C1-PD9, 1-C1-PD10, I-Cl- PDI l, I-C1-PD12, 1-C1-PD13, 1-C1-PD14, 1-Cl-PD15a, I-Cl-PD15b, I-A1-PD1, I-Al- PD2, 1-A1-PD3, 1-A1-PD4, 1-A1-PD5, 1-A1-PD6, 1-A1-PD7, 1-A1-PD8, 1-A1-PD9, I-Al- PDlO, I-A1-PD11, 1-A1-PD12, 1-A
- NOPD2a I-A3-NOPD2b, I-H1-NOPD1, 1-Hl-NOPD2a, I-Hl-NOPD2b, I-H1-NOPD3, I- H1-NOPD4, 1-Hl-N0PD5b, I-H1-NOPD6, 1-H1-NOPD7, 1-H1-NOPD8, 1-H1-NOPD9, I-H1-NOPD10, 1-AA-MPD1, 1-AA-MPD2, 1-AA-MPD3a, I-AA-MPD4, 1-AA-MPD5, I- AA-MPD6, 1-AA-MPD7, 1-AA-MPD8, 1-AA-MPD9, 1-AA-MPD10, 1-AA-MPD11, I- AA-MPD12, 1-AA-MPD13, 1-AA-MPD14, 1-AA-MPD15, 1-AA-MPD16, 1-AA-MPD17, I-AA-MPD18, 1-AA-MPD19, 1-AA-MPD20, 1-AA-MPD21
- MPD30 1-AH-MPD1, 1-AH-MPD2, 1-AH-MPD3, 1-AH-MPD4, 1-AH-MPD5, 1-AH- MPD6, 1-AH-MPD7, 1-AH-MPD8, 1-AH-MPD9, 1-AH-MPD10, 1-AH-MPD11, I-AH- MPD12, 1-AH-MPD13, 1-AH-MPD14, 1-AH-MPD15, 1-AH-MPD16, 1-AH-MPD17, I- AH-MPD 18, 1-AH-MPD19, 1-AH-MPD20, 1-AH-MPD21, 1-AH-MPD22, 1-AH-MPD23, I-AH-MPD24, 1-AH-MPD25, 1-AH-MPD26, 1-CH-MPD 1 , 1-CH-MPD2, 1-CH-MPD3, I- CH-MPD4, 1-CH-MPD5, and I-CH-MPD6 or a pharmaceutical salt thereof and one or more pharmaceutically acceptable carriers, vehicles or diluents.
- An embodiment of the invention is a method of treating a mammal or human in need thereof comprising administering a therapeutically effective amount of the pharmaceutical composition comprising the compound of formula I.
- Another embodiment of the invention is use of the above listed novel intermediates in the processes for the preparation of compounds of formula I;
- Further embodiments include methods of preparation and methods of use of compounds of formula (I) or pharmaceutically acceptable salts thereof.
- Another embodiment of the invention is process for the preparation of compounds of formula I, or pharmaceutically acceptable salts thereof, wherein the process comprises of: monoprotection of Bis-(2-hydroxyethyl)disulphide (SL-I) with an appropriate hydroxyl protecting group to give a corresponding monoprotected intermediate, conversion of the corresponding monoprotected intermediate to an activated formyl intermediate by treating with phosgene or its equivalent, and reaction of the activated formyl intermediate with an appropriate amino- or hydroxy containing D 1 to give the corresponding compound of formula I.
- Another embodiment of the invention is a process for the preparation of compounds of formula I, or pharmaceutically acceptable salts thereof , wherein the process comprises of :
- the invention is a process in which the monoprotected intermediate is LIIx, and the activated formyl intermediate is Lllxy.
- Another embodiment of the invention is a process for preparation of compounds of formula (I), wherein D 2 is NO 2 or pharmaceutically acceptable salts thereof, wherein the process comprises, mixing a selectively protected and activated Dl with a solution of
- Another embodiment of the invention is a process for preparation of compounds of formula (I), wherein D 2 is NO 2 or pharmaceutically acceptable salts thereof, wherein a process comprises, converting 2-((2-hydroxyethyl)dithio)ethyl nitrate (LI-2b) into its formyl halide or imidazolide (LI-4x) by using a phosgene or its equivalent reagent and mixing/reacting the resulting reactive intermediate with a suitable amino- or hydroxy- containing drug in suitable solvent in presence of a suitable base.
- a process comprises, converting 2-((2-hydroxyethyl)dithio)ethyl nitrate (LI-2b) into its formyl halide or imidazolide (LI-4x) by using a phosgene or its equivalent reagent and mixing/reacting the resulting reactive intermediate with a suitable amino- or hydroxy- containing drug in suitable solvent in presence of a suitable base.
- Another embodiment of the invention is a process for preparation of compounds of formula (I), wherein D 2 is NO 2 or pharmaceutically acceptable salt thereof, wherein the process comprises, mixing/reacting a selectively protected and activated drug with a solution of 2-((2-aminoethyl)dithio)ethyl nitrate (LI-5) in a suitable solvent in presence of a suitable coupling agent and/or base.
- Another embodiment of the invention is a process for preparation of mutual prodrugs of compounds of formula (I), or pharmaceutically acceptable salts thereof, wherein a process comprises,
- Further embodiments of the invention are processes for the preparation of compounds of formula I 5 or pharmaceutically acceptable salts thereof, wherein the processes comprise of the steps that are generally depicted in the schemes 1-23. Further embodiments include the pharmaceutical composition comprising a therapeutically effective amount of novel intermediates or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, vehicles or diluents.
- Another embodiment of the invention is use of compounds of formula (I) or pharmaceutically acceptable salt thereof, in the treatment of disease conditions originally treatable by the corresponding free drug(s).
- Another embodiment of the invention is double prodrug of formula (I) selected from the group consisting of: I-AA-MPD5, 1-AA-MPD6, 1-AA-MPD7, and I-AA-MPD8.
- the present invention also provides mutual prodrugs of formula (I) selected from the group consisiting of: I-CA-MPD1, I-CA-MPD2, I-CA-MPD3, I-CA-MPD4, I-CA-
- MPDI l I-CA-MPD12, I-CA-MPD13, I-CA-MPD14, I-CA-MPD15, I-CA-MPD16, I- CA-MPD17, I-CA-MPD18, I-CA-MPD19, I-CA-MPD20, I-CA-MPD21, I-CA-MPD22, I-CA-MPD23, I-CA-MPD24, I-CA-MPD25, I-CA-MPD26, I-CA-MPD27, I-CA- MPD28, 1-CA-MPD29, and I-CA-MPD30.
- the invention provides compounds of formula (I) selected from the group of mutual prodrugs made from amino-containing therapeutic agent and a hydroxyl-containing therapeutic agent such as: I-AH-MPD1, 1-AH-MPD2, 1-AH-MPD3, I-AH-MPD4, I-AH-MPD5, I-AH-MPD6, I-AH-MPD7, I-AH-MPD8, I-AH-MPD9, I- AH-MPDlO, I-AH-MPD11, 1-AH-MPD12, 1-AH-MPD13, I-AH-MPD14, 1-AH-MPD15, I-AH-MPD16, I-AH-MPD17, I-AH-MPD18, I-AH-MPD19, I-AH-MPD20, I-AH- MPD21, 1-AH-MPD22, 1-AH-MPD23, 1-AH-MPD24, 1-AH-MPD25, and I-AH-MPD26.
- a hydroxyl-containing therapeutic agent such as: I-AH-MPD1,
- Yet another embodiment of the invention relates to compounds of formula (I) of mutual prodrugs made from a hydroxyl-containing therapeutic agent and a hydroxyl- containing therapeutic agent such as: I-HH-MPD1, I-HH-MPD2, I-HH-MPD3, I-HH- MPD4, I-HH-MPD5, I-HH-MPD6, I-HH-MPD7, I-HH-MPD8, I-HH-MPD9, I-HH- MPDlO, I-HH-MPD11, I-HH-MPD12, I-HH-MPD13, I-HH-MPD14, I-HH-MPD15, I- HH-MPD16, 1-HH-MPD17, and I-HH-MPD18.
- a hydroxyl-containing therapeutic agent such as: I-HH-MPD1, I-HH-MPD2, I-HH-MPD3, I-HH- MPD4, I-HH-MPD5, I-HH-MPD6, I-HH-MPD7, I-HH-MPD
- the present invention also provides compounds of formula (I) containing water- soluble prodrugs of insoluble or sparingly-soluble therapeutic agents such as: I-H1-PD1, I-H1-PD2, 1-H1-PD3, 1-H1-PD4, 1-H1-PD5, 1-H1-PD6, 1-H1-PD7, 1-H1-PD8, 1-H1-PD9, I-H1-PD10, 1-H1-PD11, 1-H1-PD12, 1-H1-PD13, 1-A1-PD1, 1-A1-PD2, 1-A1-PD3, I-Al- PD4, 1-A1-PD5, 1-A1-PD6, 1-A1-PD7, 1-A1-PD8, 1-A1-PD9, 1-A1-PD10, I-A1-PD11, I- A1-PD12, I-A1-PD13, I-A1-PD14, I-A1-PD15A, I-Al-PDlAa, I-A1-PD15B, I-Al- PD 15
- Another embodiment of the invention relates to the compounds of formula (I), selected from the group of NO-releasing prodrugs consisting of: I-Cl -NOPDl, I-Cl- NOPD2, 1-Cl-NOPD3a, I-Cl-NOPD3b, I-C1-NOPD4, 1-Cl-NOPD5a, I-Cl-NOPD5b, I- C1-NOPD6, 1-C1-NOPD7, 1-Cl-NOPD8a, I-Cl-NOPD8b, I-C1-NOPD9, 1-C1-NOPD10, I-Cl-NOPDl la, I-C1-NOPD13, 1-Cl-NOPD14a, I-Cl-NOPD14b, I-Cl-NOPD15b, I-Cl- NOPD 16, I-Cl -NOPD 17a, I-Cl -NOPD 17b, I-C1-NOPD18, I-C1-NOPD19, I-Cl- NOPD20a, I-
- Another aspect of the invention provides the use of the compounds of formula (I) in combination with a compound used to treat cardiovascular diseases selected from the group consisting of: beta adrenergic blockers, calcium channel blockers, angiotensin II receptor antagonists, antithrombotics, HMGCoA reductase inhibitors, aspirin or nitrooxy derivatives of aspirin, nitrosated beta blockers, nitrosated or nitrosilated calcium channel blockers.
- Suitable drugs are described in the literature such as the Merck Index, IDdb, Prous Science's Integrity ® , Prous Science Drugs of the FutureTM, The Ensemble ® and the like.
- Another aspect of the invention provides the use of the pharmaceutical compositions containing compounds of formula (I) in combination with a compound, used to treat other diseases such as cardiovascular diseases, selected from beta adrenergic blockers, calcium channel blockers, angiotensin II receptor antagonists, antithrombotics, HMGCoA reductase inhibitors, aspirin or nitrooxy derivatives of aspirin, nitrosated beta blockers, nitrosated or nitrosilated calcium channel blockers.
- Pharmaceutical compositions containing two or more of compounds of the invention can be used for the purpose of combination therapy. These pairs of compounds of invention can be from the same therapeutic area or from different therapeutic areas for treating one or more diseases or conditions.
- the compounds of the invention which have one or more asymmetric carbon atoms, can exist as the optically pure enantiomers, pure diastereomers, enantiomer racemic mixtures, diastereomer racemic mixtures, racemates or racemate mixtures.
- optically pure enantiomers pure diastereomers
- enantiomer racemic mixtures pure diastereomers
- diastereomer racemic mixtures diastereomer racemic mixtures
- racemates or racemate mixtures are also all the possible isomers, stereoisomers and their mixtures of the compounds of formula (I).
- Another embodiment of the invention relates to the pharmaceutical composition comprising one or more compounds of formula (I) or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable carriers, vehicles or diluents.
- Another embodiment of the invention relates to the pharmaceutical composition comprising one or more compounds of formula (I) or pharmaceutically acceptable salts thereof and at least another pharmaceutically active compound.
- the pharmaceutically active compound can be from the same or different therapeutic areas for treating one or more disease condition(s) together with one or more pharmaceutically acceptable carriers, vehicles or diluents.
- Another embodiment of the invention is a process for preparation of compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein the process comprises, mixing a selectively protected and activated drug with a solution of 2-((2- hydroxyethyl)dithio)ethyl nitrate in a suitable solvent in presence of a suitable coupling agent.
- Another embodiment of the invention is a compound or intermediate generated in the above methods and processes.
- Another embodiment of the invention is a process for preparation of compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein a process comprises, converting 2-((2-hydroxyethyl)dithio)ethyl nitrate into its formyl halide or imidazolide by using a phosgene or its equivalent reagent and mixing/reacting the resulting reactive intermediate with a suitable drug in suitable solvent in presence of a suitable base.
- Another embodiment of the invention is a process for preparation of compounds of formula (I) or pharmaceutically acceptable salt thereof, wherein the process comprises, mixing/reacting a selectively protected and activated drug with a solution of 2-((2- aminoethyl)dithio)ethyl nitrate (or its acid salt) in a suitable solvent in presence of a suitable coupling agent and/or base.
- Another embodiment of the invention comprises the novel intermediates formed in the preparation of present invention.
- Further embodiments include a pharmaceutical composition comprising a therapeutically effective amount of novel intermediates or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, vehicles or diluents.
- Another embodiment of the invention is processes for the preparation of compounds of formula (I) or pharmaceutically acceptable salt thereof, as well as the starting materials and intermediates involved as depicted in schemes 1-23.
- Another embodiment of the invention is use of compounds of formula (I) or pharmaceutically acceptable salts thereof, in the treatment of disease conditions originally treatable by the corresponding free drugs.
- Another embodiment of the invention includes but not limited to a pharmaceutical composition
- a pharmaceutical composition comprising the compounds of formula (I), or pharmaceutically acceptable salt thereof, selected from the group of NO-releasing prodrugs described herein, or more pharmaceutically acceptable carriers, vehicles or diluents.
- a Mutual Prodrug of desloratadine and pseudoephedrine (I-AA-MPD1) is proposed as a potential treatment option for seasonal allergic rhinitis (SAR).
- Desloratadine an active metabolite of loratadine
- Pseudoephedrine is an oral decongestant.
- a Mutual Prodrug of amlodipine (Pfizer' s Norvasc ® ) and lisinopril (Zeneca's Zestril ® ) (I-AA-MPD2) is proposed as a potential treatment option for hypertension and congestive heart failure.
- Amlodipine is a calcium channel blocker and is used as an antihypertensive and antianginal agent.
- Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor and is used for the treatment of hypertension and congestive heart failure.
- ACE angiotensin-converting enzyme
- a Mutual Prodrug of amlodipine (Pfizer' s Norvasc ® ) and losartan (Merck's Cozaar ® ) (I-AA-MPD3a) is proposed as a potential treatment option for mild to moderate hypertension.
- Amlodipine is a calcium channel blocker and is used as an antihypertensive and antianginal agent.
- Losartan potassium is an angiotensin II blocker and is used for the treatment of hypertension.
- a combination therapy using these two drugs has been proven to be more effective treatment option than monotherapy using either of these drugs.
- Examples of mutual prodrugs and double prodrugs of valdecoxib and celecoxib containing a disulfide linker are: I-AA-MPD4 and I-AA-MPD5.
- Examples of double prodrugs of valdecoxib or celecoxib containing non-disulfide linkers I-AA-MPD6, 1-AA-MPD7, 1-AA-MPD8.
- Zyprexa ® (I-AA-MPD9) is proposed for potential treatment of patients with Bipolar disorder. Fluoxetine and Olanzapine are used in combination to treat patients with bipolar disorder while being spared the treatment-emergent mania that such patients often get on antidepressant monotherapy.
- Example of double prodrug of gabapentin is proposed as potential antiepileptic agent: I-AA-MPD10.
- mutual prodrugs under this category include the following: Mutual prodrugs of valproic acid and other carboxyl-, hydroxyl-, and amino- containing (including amide-, and sulfonamide-containing) anticonvulsant agents such as levetiracetam, lamotrigine, pregabalin, carbamazepine, oxcarbamazepine, licarbazepine, felbamate, topiramate and the like. (Structures are given below).
- the list also includes investigational antiepileptic agents such as antipamezole, licarbazepine, Eslicarbazepine Acetate (BIA 2-093), fluorofelbamate, isovaleramide (NPS 1776), retigabine (D-23129), safmamide (NW-IOl 5), stiripentol (STP), talampanel (TLP), (2S)-2-[(4R)-2-oxo-4- propylpyrrolidin-l-yl]butanamide 83 alpha (ucb 34714), valrocemide (TV 1901), and the like.
- investigational antiepileptic agents such as antipamezole, licarbazepine, Eslicarbazepine Acetate (BIA 2-093), fluorofelbamate, isovaleramide (NPS 1776), retigabine (D-23129), safmamide (NW-IOl 5), stiripentol (STP
- Mutual Prodrugs can be made from combination of any two anti-convulsant agents listed above or any other suitable anticonvulsant agents.
- Mutual prodrug of gabapentin and naproxen (I-CA-MPD22) is proposed for potential treatment option for neurological pain and inflammation.
- Metronidazole is an antianaerobic agent and used in combination with antibiotics such as norfloxacin, ciprofloxacin, etc. for the treatment of patients with diarrhea and dysentery of bacterial, amoebic and mixed origin.
- a mutual prodrug of loperamide and.norflaxacin (I-AH-MPD4) is proposed for potential treatment of diarrhea and dysentery.
- a mutual prodrug of valdecoxib and tramadol (I-AH-MPD5 and I-AH-MPD6) as a potential therapy in postoperative pain management.
- a mutual prodrug of gabapentin and tramadol ⁇ (I-AH-MPD7) is proposed for potential treatment of neuropathic pain after spinal cord injury.
- I-AH-MPD8 A mutual prodrug of venlafaxine and paroxetine (I-AH-MPD8) is proposed for potential treatment of neurological and depression related disorders.
- Water-soluble prodrugs of insoluble/sparingly-soluble therapeutic agents can be prepared using the same linker technology.
- Water-soluble prodrugs of metronidazole include: I-H1-PD-2, I-H1-PD-3, I-Hl- PD-4.
- Water-soluble prodrugs of valdecoxib include: I-A3-PD1, I-A3-PD2a, I-A3- PD2b, I-A3-PD3a, I-A3-PD3b, I-A3-PD4, 1-A3-PD5, 1-A3-PD6, and I-A3-PD7b.
- Water-soluble prodrugs of paclitaxel include: I-Taxol-PDl, I-Taxol-PD2, 1-Taxol- PD3, 1-Taxol-PD4, 1-Taxol-PD5, 1-Taxol-PD6, and I-S23-PD1.
- R 1 is H, alkyl, aralkyl, or a metal ion
- Drugs can be released form the prodrugs and mutual prodrugs via cleavage of bio- labile linker(s) in vivo (cleavage can be either chemical or enzymatic or both) by illustrative mechanisms as shown in Schemes Ml through M5.
- nitric oxide (NO) and free drug from NO-releasing prodrug(s) of amino-, hydroxyl-, or carboxyl-containing drug(s) are illustratively shown in Schemes Ml .
- the attack of thiolate ion (from GSH or any other sulfahydryl-containing species) on nitrooxy-containing prodrug would release carboxylic acid-containing free drug, episulfide (d) and the intermediate conjugate (a) according to path 1.
- the prodrug would be cleaved via path 2 to release the corresponding free drug, the cyclic thiocarbonate intermediate (c) and the intermediate conjugate (a).
- the cyclic thiocarbonate intermediate may further breakdown into episulfide (d) and carbon dioxide.
- the reactive episulfide (d) would be further neutralized by glutathione.
- the nitrate ester- containing intermediate conjugate can further break down in the presence of GSH to glutathione dimer (GS-SG) and transient intermediate (b), which can break down via path 3 to release NO. It is also possible the same transient intermediate can break down via path 4 to yield episulf ⁇ de (d) and a relatively innocuous nitrate anion (NO 3 " ).
- Scheme Ml Plausible mechanisms of drug release from mutual prodrugs of one carboxyl- containing and one amino-/hydroxyl-containing drug is shown in Scheme M2.
- D ⁇ D 2 and L 2 are as defined in the text.
- X m2 is a bond, CH 2 , O, NR ml (R ml is H, alkyl, aryl or a bond),
- This invention also covers novel bio-labile linkers containing 1 ,4-phenylene group and 1 ,2-phenylene group as shown in Schemes 5 and 6, respectively.
- the linker is expected to release the free Drug 1 upon glutathione-assisted cleavage and may generate 1,4-quinonemethid (ea) as a byproduct via 1,6-elimination process.
- the free Drug 2 is expected to be released from the intermediate conjugate (a) as shown in the scheme.
- the 1,2-phenylene-containing linker is also expected to release free drugs upon glutathione assisted cleavage and genereate 1,2-quinonemethid (eb) as a byproduct via 1,4-elimination process (via pathway 'b').
- this linker can also cleave via pathway 'a' to generate benzo-monothiocarbonate as a byproduct.
- the generated byproducts seem to be toxic, they are likely to be quickly neutralized by detoxification enzymes in the body.
- Diazepam a benzodiazepine tranquilizer
- a water-soluble acyclic prodrug of diazepam can be made by using our linker technology.
- reduction of disulfide bond in the prodrug triggers release of open-chain intermediate of diazepam which spontaneously cyclizes to diazepam in vivo.
- GSH is glutathione (reduced) or any other in vivo bioreductive agent that can reduce the disulfide bond.
- cleavage of disulfide bond triggers further breakage of the remaining portion of the linker to release the free drugs. In the process, some byproducts are generated and these are either eliminated or further degraded by some biological process. For clarity, the mechanism of cleavage of the linker is shown as occurring in stepwise manner. However, both the steps can possibly occur in a concomitant fashion to release both the drugs simultaneously.
- Linkers may have additional spacer groups between one side (or both sides) of the linkers and the drug molecule and some of these spacer groups may be cleaved independently by a chemical or enzymatic process to release the drugs prematurely before the cleavage of disulfide linkage.
- the prodrugs and mutual prodrugs containing such spacer groups may be useful when faster release of drug(s) is desired.
- Drugs listed in the following list can be converted to NO- releasing prodrugs. This list is in no way limiting the scope of drugs covered in this invention, but given as representative examples. All the amino- (including amide-NH and sulfonamide-NH, carbamate-NH, sulfamate-NH, hydrazone-NH, semicarbazone-NH, thiosemicarbazone- NH, urea-NH, phosphoramide-NH and the like.
- ANTI-INFLAMMATORY DRUGS Amino-containing (including Amide NH and Sulphonamide NH and
- Phosphomide NH etc.: Ampiroxicam, Bucolome, Celecoxib, Difenpiramide, Mofebutazone, Nimesulide, Paranyline, Parecoxib, Parsalmide, Piketoprofen, Talniflumate, Tenidap, Terofenamate, and Valdecoxib.
- Hydroxyl-containing 21-Acetoxypregnenolone, Alclometasone, alfa-Bisabolol, Budesonide, Deflazacort, Diflorasone, Desonide, Desoximetasone, Diflorasone, Diflucortolone, Difiuprednate, Ditazol, Fluazacort, Fluocinonide, Fluocortin Butyl, Fluprednidene Acetate, Glucametacin, Halcinonide, Halobetasol Propionate, Halometasone, Halopredone Acetate, Ibuproxam, Loteprednol Etabonate, Mazipredone, Mometasone Furoate, Oxyphenbutazone, Perisoxal, Rimexolone, Hydroxyl-, and Amino-containing (including Amide NH and Sulphonamide NH and Phosphomide NH, etc.): Bufexamac, Etof
- Hydroxyl- and sulphahydryl-containing Tixocortol, Carboxyl- and Amino-containing (including amide NH and sulphonamide NH and phosphomide NH, etc.): Aceclofenac, Alminoprofen, Amfenac, 3-Amino-4- hydroxybutyric Acid, Carprofen, Diclofenac, Enfenamic Acid, Etodolac, Flufenamic Acid, Meclofenamic Acid, Mefenamic Acid, Niflumic Acid, and Tolfenamic Acid.
- Carboxyl-containing Acemetacin, Acetamidocaproic Acid, Bendazac, Benoxaprofen, Be ⁇ noprofen, Bucloxic Acid , Butibufen, Cinmetacin, Clidanac, Clopirac, Felbinac, Fenbufen, Fenclozic Acid, Fenoprofen, Fentiazac, Flunoxaprofen, Flurbiprofen, Ibuprofen, Indomethacin, Isofezolac, Isoxepac, Ketoprofen, Lonazolac, Loxoprofen, Metiazinic Acid, Mofezolac, Naproxen, Oxaprozin, Pirazolac, Pirprofen, Pranoprofen, Protizinic Acid, Sulindac, Suprofen, Suxibuzone, Tiaprofenic Acid, Tolmetin, and Tropesin.
- Carboxyl- and Hydroxy 1-containing Balsalazide
- Olsalazine Olsalazine, Oxaceprol, and Ximoprofen.
- Amino-, Carboxyl- and Hydroxyl-containing 3-Amino-4-hydroxybutyric Acid, Mesalamine, and Sulfasalazine.
- Keto-containing Nabumetone, and Piketoprofen.
- Carboxyl- and keto-contianing Bermoprofen, Bucloxic Acid, Isoxepac,
- Ketoprofen, Loxoprofen, and Zaltoprofen are Ketoprofen, Loxoprofen, and Zaltoprofen. ANALGESIC AND/OR ANTIPYRETIC DRUGS:
- Amino-containing Aminochlorthenoxazin, Aminopropylon, Anileridine,
- Phenacetin Phenazopyridine, Phenocoll, Phenopyrazone, Piminodine, Piritramide,
- Hydroxyl-containing Aluminum bis(acetylsalicylate), Benzylmo ⁇ hine, Bupreno ⁇ hine, Butorphanol, Chlorobutanol, Ciramadol, Codeine, Desomo ⁇ hine, Dihydrocodeine, Dihydromorphine, Dihydroxyaluminum acetylsalicylate, Dimepheptanol, Eptazocine, Ethylmorphine, Eugenol, Hydroxypethidine, Levo ⁇ hanol, Meptazinol, Metazocine, Mo ⁇ hine, Nalbuphine, Pentazocine, Phenazocine, Phenoperidine, Phenylsalicylate, Salicin, Tramadol, and Viminol.
- Carboxyl-containing Acetylsalicylsalicylic acid, Alclofenac, Aspirin, Benoxaprofen, 5-Bromosalicylic acid acetate, Cinchophen, Diacerein, Dipyrocetyl, Fosfosal, Ibufenac, Indoprofen, and Salicysulfuric acid.
- Amino- and Hydroxyl-containing Acetaminophen, Acetaminosalol, Bucetin, Capsaicine, Dezocine, Floctafenine, Glafenine, Isoladol, p-Lactophenetide, Norlevorphanol, No ⁇ norphine, Phenylramidol, Salacetamide, and Salicylamide.
- Amino- and Carboxyl-containing Actarit, Bumadizone, Clonixin, and Salicylamide O-acetic acid.
- Carboxyl- and Hydroxyl-containing Diflunisal, Gentisic acid, and Salsalate.
- Keto-containing Amtolmetin, Dipipanone, Hydrocodone, Isomethadone, Methadone, Norpipanone, and Phenadoxone.
- Hydroxy- and Keto-containing Hydromorphone, Ketobemidone, Metopon, Oxycodone, and Oxymorphone.
- Carboxyl- and Keto-containing Clometacin, Ketorolac, and Zomepirac.
- Amino-containing Alfuzosin, Benzylhydrochlorothiazide, Bethanidine, Bopindolol, Budralazine, Bunazosin, Ciclosidomine, Clonidine, Clopamide,
- Reserpiline Reserpine, Rilmenidine, Syrosingopine, Tasosartan, Terazosin, Tiamenidine,
- Hydroxy-containing Ajmaline, Cicletanine, Levcromakalim, Naftopidil, Phenactropinium chloride, and Protoveratrines.
- Carboxyl-containing Eprosartan, Fosinopril, and Telmisartan,
- Amino- and Carboxyl-containing Alacepril, gama-Aminobutyric acid, Benazepril, Candesartan, Carmoxirole, Caronapril, Cilazapril, Delapril, Enalapril, Enalaprilat, Imidapril, Lisinopril, Moexipril, Moveltipril, Perindopril, Quinapril, Ramipril, Saralasin, Spirapril, Temocapril, Trandolapril, and Valsartan.
- Amino- and Hydroxyl-containing Acebutolol, Alprenolol, Amosulalol, Arotinolol, Atenolol, Betaxolol, Bisoprolol, Bosentan, Bucindolol, Bufeniode, Bunitrolol, Bupranolol, Butofilolol, Cadralazine, Celiprolol, Carazolol, Carteolol, Cetamolol, Carvedilol, Epanolol, Indenolol, Nadolol, Dilevalol, Fenoldopam, Guanoxabenz, Labetalol, Losartan, Mepindolol, Metipranolol, Metoprolol, Moprolol, Nebivolol, Olmesartan, Oxprenolol, Penbutolol, Phentolamine, Pildralazin
- Amino-containing Acedapsone, Acetosulfone sodium, Ambazone, Bacampicillin, Benzylsulfamide, Brodimoprim, Cefcapene pivoxil, Cefpodoxime proxetil, Chloramine- B, Chloramine-T, Capreomycin, Clofazimine, Cyacetacide, Cycloserine, Dapsone, Ethionamide, Furazolium chloride, N2-Formylsulf ⁇ somidme, Furonazide, Isoniazid, Lenampicillin, Linezolide, Mafenide, 4'-(Methylsulfamoyl)sulfanilanilide, Morphazinamide, Nifuradene, Nitrofurantoin, Penamecillin, Penethamate hydriodide, Pexiganan, Pivampicillin, Pivcefalexin, Picloxydine, Protionamide, Pyrazinamide, Solasulfone, Suba
- Hydroxyl-containing Azithromycin, Chloroxylenol, Chlorquinadol, Clofoctol, Cloxyquin, Diathymosulfone, Glucosulfone sodium, Nifurpirinol, Nifurtoinol, Nitroxoline, Roxarsone, Roxithromycin, Xanthocillin, and Xibornol.
- Carboxyl-containing (including sulfate, phosphate and phosphonate-containing): Amdinocillin, Cinoxacin, Difloxacin, Fosfomycin, and Hydnocarpic acid.
- Amino- and Carboxyl-containing (including sulfate-, sulfonic acid-, phosphate and phosphonate-containing): Acediasulfone, Amphomycin, Ampicillin, Azidocillin, Azlocillin, Aztreonam, Bacitracin, Balofioxacin, Betamipron, Carbenicillin, Carindacillin, Carumonam, Cefaclor, Cefazedone, Cefazolin, Cefclidin, Cefditoren, Cefepime, Cefetamet, Cefixime, Cefmenoxime, Cefmetazole, Cefodizime, Ceforanide, Cefotaxime, Cefotetan, Cefotiam, Cefoxitin, Cefozopran, Cefpimizole, Cefpirome, Cefroxadine, Cefsulodin, Ceftazidime, Cefteram, Ceftezole, Ceft
- Amino- and Hydroxyl-containing Amikacin, p-Aminosalicylic acid hydrazide, Arbekacin, Azidamfenicol, Bambermycins, 5-Bromosalicylhydroxamic acid, Butirosin, Clindamycin, Clomocycline, Chloramphenicol, Cloxacillin, Colistin, Demeclocycline, Deoxydihydrostreptomycin, Dibekacin, Dihydrostreptomycin, Dirithromycin, Doxycycline, Enviomycin, Ethambutol, Forimicins, Gentamycin, Glyconiazide, N4-beta- D-Glucosylsulfanilamide, Gramicidin(s), Isepamicin, Kanamycin(s), Lincomycin, Meclocycline, Methacycline, Micronomicin, Neomycin, Netilmicin, Novobiocin, Paromomycin, Phenyl aminosalicylate, Pi
- Hydroxyl- and Carboxyl-containing including sulfate, phosphate and phosphonate-containing: Fropenem, Nadifloxacin, Biapenem, Fusidic acid, and Merbromin. Hydroxyl- and Aldehyde-containing: Josamycin, Leucomycins, Midecamycins,
- Amino-, Hydroxyl-, and Carboxyl-containing including sulfate, phosphate and phosphonate-containing: p-Aminosalicylic acid, Apicycline, Amoxicillin, Apalcillin, Aspoxicillin, Benzoylpas, Cefadroxil, Cefamandole, Cefatrizine, Cefbuperazone, Cefdinir, Cefminox, Cefonicid, Cefoperazone, Cefoselis, Cefpiramide, Cefprozil, Ertapenem, Flomoxef, Imipenem, Lymecycline, Meropenem, Moxalactam, Negamycin, Panipenem, Ritipenem, Salazosulfadimidine, Sulfaloxic acid, 4-Sulfanilamidosalicylic acid, Teicoplanin, Tyrocidine, and Vancomycin.
- Keto-containing Troleandomycin. Hydroxy- and Keto-containing: Carbomycin, Clarithromycin, Erythromycin, all erythromycin ester derivatives, Oleandomycin, and Telithromycin.
- Carboxyl- and Keto-containing Fleroxacin, Flumequine, Miloxacin, Nalidixic acid, Ofloxacin, Oxolinic acid, Pefloxacin, Piromidic acid, Prulifloxacin, Rosoxacin, and Rufloxacin.
- Amino-, hydroxyl-, and Keto-containing Chlortetracycline, Dalfopristin, Guamecycline, Mikamycin, Minocycline, Oxytetracycline, Pristinamycin, Quinupristin, Rolitetracycline, Spectinomycin, and Trospectomycin.
- Amino-, carboxyl-,and keto-contianing Garenoxacin, Gatifloxacin, Gemifloxacin, Grepafloxacin, Lomefloxacin, Moxifloxacin, Norfloxacin, Pazufloxacin, Pipemidic acid, Sitafloxacin, Sparfloxacin, Tosufloxacin, and Trovafloxacin.
- Amino-containing Chlordantoin, Exalamide, Flucytosine, Loflucarban, Magenta I, and Pyrrolnitrin.
- Hydroxy-containing Chlo ⁇ henesin, Ciclopirox, Dermostatin, Filipin, Fluconazole, Fungichromin, Pecilocin, Posaconazole, Ravuconazole, Rubijervine, Siccanin, 2,4,6-Tribromo-m-cresol and Voriconazole.
- Amino- and Carboxyl-containing Azaserine.
- Amino- and Hydroxyl-containing Salicylanilide, Acrisorcin (9-Aminoacrindine compound with 4-Hexylresorcinol (1:1)), Anidulafungin, Bromosalicylchloranilide, Buclosamide, Caspofungin, Micafungin, and Tubercidin.
- Amino-, Carboxyl- and Hydroxyl-containing Natamycin, Amphotericin B, Lucensomycin, and Nystatin.
- Carbonyl-containing sodium propionate and griseofulvin. Hydroxy- and carbonyl-containing: Viridin.
- Amino-, hydroxyl-, and carbonyl-containing Perimycin and Mepartricin. Amino-, carboxyl-, hydroxyl-, and carbonyl-containing: Candicidin. ANTIVIPVAL DRUGS:
- Edoxudine Hydroxy-containing: Edoxudine, Floxuridine, Idoxuridine, Kethoxal, Podophyllotoxin, Sorivudine, Stavudine, Trifluridine, and Zidovudine.
- Amino-containing Amantadine, Amidinomycin, Atevirdine, Capravirine, Delavirdine, Efavirenz, Famciclovir, Imiquimod, Lamivudine, Methisazone, Moroxydine, Nevirapine, Oseltamivir, Rimantadine, Stallimycin, mantadine, and Valacyclovir.
- Amino- and Hydroxyl-containing Abacavir, Acyclovir, Adefovir, Amprenavir,
- Atazanavir Cidofovir, Didanosine, Dideoxyadenosine, Emtricitabine, Entecavir, Indinavir, Lamivudine, Lopinavir, 5-(methylamino)-2-deoxyuridine (MADU), Nelfinavir, Penciclovir, Resiquimod, Ribavirin, Ritonavir, Saquinavir, Tenofovir, Tipranavir, Valganciclovir, Vidarabine, and Zalcitabine.
- Carboxyl- and Hydroxyl-containing Foscarnet sodium, and Ganciclovir. Amino-, Carboxyl- and Hydroxyl-containing: Zanamivir.
- Amino-containing Chlorguanide, Chloroquine, Chlorproguanil, Cycloguanil, Pamaquine, Plasmocid, Primaquine, Quinocide, and Tafenoquine.
- Hydroxyl-containing Artemisinin alcohol, Bebeerines, Cinchonidine, Cinchonine, Dihydroartemisinin, Halofantrine, Lumefantrine, Quinine and Yingzhaosu A.
- Carboxyl-containing Arteflene and Artesunate.
- Amino-, and Hydroxyl-containing Amodiaquin, Hydroxychloroquine, Mefloquine, and Pyronaridine. Hydroxyl, and carbonyl-containing: Fosmidomycin.
- Carbonyl-containing Arteflene.
- ANTINEOPLASTIC DRUGS
- Calusterone Capecitabine, CC- 1065, Chromomycins, Diethylstilbestrol, Docetaxel, Doxifluridine, Droloxifene, Dromostanolone, Enocitabine, Epitiostanol, Estramustine,
- Etanidazole Etoposide, Fenretinide, Flavopiridol, Formestane, Fosfestrol, Fulvestrant,
- Paclitaxel and other known paclitaxel analogs Plicamycin, Podophyllotoxin, Retinoic acid (including all trans-retinioc acid), Roquinimex, Rubitecan, Seocalcitol, Temoporf ⁇ n,
- Amino-containing including Amide-NH and Sulphonamide-NH, Carbamate-NH,
- Sulfamate-NH, and Phosphomide-NH 9-Aminocamptothecin, Aminolevulinic Acid, Amsacrine, Bisantrene, Cactinomycin, Carboquone, Carmofur, Carmustine,
- Cyclophosphamide dacarbazine, Dactinomycin, Demecolcine, Diaziquone, 6-Diazo-5- oxo-L-norleucine (DON), Edatrexate, Efaproxiral, Eflornithine, Eniluracil, Erlotinib, Fluorouracil, Gefitinib, Gemcitabine, Goserelin, Histamine, Ifosfamide, Imatinib, Improsulfan, Lanreotide, Leuprolide, Liarozole, Lobaplatin, Cisplatin, Carboplatin, Lomustine, Lonafarnib, Mannomustine, Melphalan, Methotrexate, Methyl Aminolevulinate, Miboplatin, Mitoguazone, Mitoxantrone, Nilutamide, Nimustine, Nolatrexed, Oxaliplatin, Pemetrexed, Phenamet, Piritrexim,
- Both Hydroxy- & Amino- containing (including Amide-NH and Sulphonamide- NH, Carbamate-NH, Sulfamate-NH, and Phosphomide-NH): Ancitabine, Anthramycin, Azacitidine, Bleomycins, Bropirimine, Buserelin, Carubicin, Chlorozotocin, Cladribine, Cytarabine, Daunorubicin, Decitabine, Defosfamide, Docetaxel, Doxorubicin, Ecteinascidins, Epirubicin, Gemcitabine, Hydroxyurea, Idarubicin, Marimastat, 6- Mercaptopurine, Pentostatin, Peplomycin, Perfosfamide, Pirarubicin, Prinomastat, Puromycin, Ranimustine, Streptonigrin, Streptozocin, Tiazofurin, Troxacitabine, Vindesine and Zorubicin. Carboxyl-containing: Butyric acid
- Amino-containing including some investigational drugs: BTX-51072 (4,4- dimethyl-3,4-dihydro-2H-l,2-benzoselenazine), Carnosine, Melatonin, (+)-R- Pramipexole, and Stobadine.
- Hydroxyl-containing including some investigational drugs: Ascorbic acid,
- Carboxyl-containing including some investigational drugs: N-Acetyl L-cysteine,
- Amino-/Hydroxyl-, and Carboxyl-containing including some investigational drugs: N-Acetyl carnosine, L-Carnitine, and SCMC-Lys (S-carboxymethyl-L-cysteine Lysine salt H 2 O).
- Amino- and Hydroxyl-containing including some investigational drugs: BN- 82451, and Zeatin.
- Amino-containing (including Amide NH and Sulphonamide NH and Phosphomide NH, etc.): Aldioxa, Benexate HCl, Cimetidine, Ebrotidine, Ecabapide,
- Esaprazole Esaprazole, Esomeprazole, Famotidine, Irsogladine, Lafutidine, Lansoprazole,
- Carboxyl-containing Acetoxolone, Carbenoxolone, Rebamipide, and Sofalcone.
- Amino (or Hydroxyl) - and Carboxyl-containing Cetraxate, Ecabet, S- Methylmethionine, Rosaprostol, and Rotraxate.
- Carbonyl-containing Spizofurone, and Teprenone.
- Amino-containing including Amide NH and Sulphonamide NH
- Ethosuximide Ethotoin, Felbamate, Fosphenytoin, Lamotrigine, Levetiracetam, Mephenytoin, Mephobarbital, Metharbital, Methetoin, Nitrazepam, Oxcarbazepine,
- Phenylmethylbarbituric Acid Phenytoin, Phethenylate Sodium, Primidone, Progabide,
- Valpromide Zonisamide, 5-Methyl-5-(3-phenanthryl)hydantoin, and 3-Methyl-5- phenylhydantoin.
- Hydroxyl-containing Ganaxolone.
- Hydroxyl-, and Amino-containing including Amide NH and Sulphonamide NH and Phosphomide NH: 4-Amino-3-hydroxybutyric Acid, Atrolactamide, and Buramate.
- Carboxyl- and Amino-Containing including Amide NH and Sulphonamide NH and Phosphomide NH: Gabapentin, Pregabalin, and Vigabatrin.
- Carboxyl-containing Tiagabine, and Valproic Acid.
- ANTIP ARKINSON'S Levodopa & Carbidopa.
- ANTIDEPRESSANT
- Amino-containing (including Amide NH and Sulphonamide NH and Phosphomide NH, etc.): Amoxapine, Caroxazone, Demexiptiline, Desipramine, Duloxetine, Fluoxetine, Fluvoxamine, Indalpine, Indeloxazine Hydrochloride, Iproclozide, Iproniazid, Isocarboxazid, Levophacetoperane, Maprotiline, Metapramine, Milnacipran, Minaprine, Moclobemide, Nialamide, Nomifensine, Nortriptyline, Octamoxin, Oxypertine, Paroxetine, Protriptyline, Reboxetine, Rolipram, Sertraline, Tofenacin, Tranylcypromine, Viloxazine, Benmoxine, and Rolicyprine. Hydroxyl-containing: Befloxatone, Bupropion, Fenpentadiol,
- Carboxyl- and Amino-Containing (including Amide NH and Sulphonamide NH and Phosphomide NH): Amineptine, and Tianeptine.
- ANTIHISTAMINIC Amide NH and Sulphonamide NH and Phosphomide NH
- Amino-containing (including Amide NH and Sulphonamide NH and Phosphomide NH, etc.): Antazoline, Astemizole, Clobenzepam, Desloratadine, Epinastine, Metron S, Mizolastine, and Tritoqualine.
- Hydroxyl-containing Terfenadine, and N-Hydroxyethylpromethazine Chloride.
- Carboxyl-containing Acrivastine, Bepotastine, Cetirizine, and Levocabastine,
- CARDIOPROTECTIVE AGENT Trans-Resveratrol [(E)-3,4',5-trihydroxystilbene).
- ANTIDIABETIC Metformin, and Nateglinide/Glipizide/Glibenclamide (Glyburide).
- any amino-, and/or carboxyl-, and/or carbonyl-, and/or hydroxyl-containing drug(s) (both known and investigational drugs) from the following therapeutic areas are covered without any limitation: CENTRAL NERVOUS SYSTEM: Sedatives, Hypnotics, Antidepressants,
- Antipsychotics and Antimanics Analgesics & Antipyretics, Antimigraine agents, Anticonvulsants, Drugs used in parkinsonism and movement disorders, Drug for dementia, Antiemtics, drugs for Vertigo, CNS Stimulants & activators.
- EYE Antiinfective eye preparations, Antiinflammatory and antiallergic preparations, antiglucoma drugs and other preparations to cure eye diseases.
- EAR, NOSE and OROPHARYNX Drugs used aural, nasal and oropharyngeal preparation.
- CARDIOVASCULAR SYSTEM Antiarrhythemic drugs, Antihypertensives (including alfa/beta-blockers, channel blockers, ACE inhibitors, Angiotensin II receptor antagonists, diuretics, etc.), Antianginals (includinig nitrates, calcium channel blockers, etc.), Drugs for cardiac failure and shock, Vasodilators, Coagulants, Anticoagulants, Thrombolytics and antiplatelet drugs.
- Antiarrhythemic drugs including alfa/beta-blockers, channel blockers, ACE inhibitors, Angiotensin II receptor antagonists, diuretics, etc.
- Antianginals includinig nitrates, calcium channel blockers, etc.
- Drugs for cardiac failure and shock Vasodilators, Coagulants, Anticoagulants, Thrombolytics and antiplatelet drugs.
- RESPIRATORY SYSTEM Respiratory stimulants, Antitussives, Expectorants, Mucolytics and Decongestants, Antihistamine agents, and antiasthmatics.
- GASTRO INTESTINAL TRACT Antiulcer and Antisecretory drags (including
- H 2 receptor antagonists include Proton Pump Iinhibitors, Prostaglandin analogues, etc.), Antacids, Antispasmodics and drugs modifying intestinal motility, Antidiarrhoeals (including antimotility and antimicrobial drugs) and drugs acting on gall bladder.
- Urinary antiinfectives Urinary antiinfectives, Diuretics, Urinary analgesics & antispasmodics, Antiinfective drugs acting on urethra and vagina, drugs acting on uterus, Drugs for prostatic hypertrophy (including alfa blockers and antiandrogens), Drugs for erectile dysfunction, and Spermicidal & nonhormonal contraceptives.
- SKIN Emollients and keratolytics, topical antiinfectives, topical antifungals, topical parasiticidals, topical steroids, topical drugs for acne vulgaris, drugs for psoriasis, pigmentation disorders, and Antiseborrhoeics.
- MUSCULO-SKELETAL DISORDERS Non Steroidal Anti Inflammatory Drugs (NSAIDs) including COX-2 inhibitors, Antiarthritic agents, Immunosuppressants, Topical analgesics, Muscle relaxants and Neuromuscular Drugs.
- NSAIDs Non Steroidal Anti Inflammatory Drugs
- COX-2 inhibitors including COX-2 inhibitors, Antiarthritic agents, Immunosuppressants, Topical analgesics, Muscle relaxants and Neuromuscular Drugs.
- INFECTIONS AND INFESTATIONS Penicillin antibiotics, Cephalosporin antibiotics, Quinolone & Fluoroquinolone antibiotics, Macrolide antibiotics,
- Anthelminthics & Antiinfestive Drugs, Antimalarials and Antivirals are Anthelminthics & Antiinfestive Drugs, Antimalarials and Antivirals.
- ENDOCRINE SYSTEM Anabolic and androgenic steroids, Corticosteroids, Oestrogens, Progestogens and Hormonal contraceptives, Fertility Agents, Trophic hormones and related drugs, Thyroid and antithyroid drugs, Antidiabetics and hyperglycaemics.
- METABOLISM Hypolipidaemic drugs (including f ⁇ bric acid derivatives, statins [(i.e., HMG CoA reductase inhibitors), nicotinic acid group, etc.], Drugs used for Gout and Drugs affecting bone metabolism (including bisphosphonates).
- NEOPLASTIC DISORDERS Anticancer drugs such as alkylating agents, cytotoxic antibiotics, antimetabolites such as cytarbine, Fludarbine, 5-Fluorouracil,
- ALLERGY AND IMMUNOLOGY Antiallurgics such as non-sedative antihistamins (e.g., Cetirizine, Desloratadine, Terfenadine, Fexofenadine, etc.), sedative histamines and histamine receptor blockers.
- non-sedative antihistamins e.g., Cetirizine, Desloratadine, Terfenadine, Fexofenadine, etc.
- sedative histamines e.g., Cetirizine, Desloratadine, Terfenadine, Fexofenadine, etc.
- ANAESTHETICS & SURGICALS Local anaesthetics, intravenous anaesthetics, inhalation anaesthetics and muscle relaxants.
- NO-releasing prodrugs of any two or more drugs from the above lists of potential drugs can be used in combination depending on the medical application/need. While a combination formulation may occassionally consist of more than two drugs (depending on the medical need), the following pairs of drugs are covered in this invention as illustrative pairs of candidate drugs for combination therapy.
- ANTICANCER Paclitaxel and Doxorubicin, Paclitaxel and Mitomycin C; Paclitaxel and 9-aminocamptothecin, 3-Arninopyridine-2-carboxaldehyde thiosemicarbazone (3-AP)/ 3-Aminopyridine-4-methyl-2-carboxaldehyde thiosemicarbazone (3 -AMP) and another known anticancer drug such as Paclitaxel,
- Doxorubicin, Mitomycin C and the like CC- 1065 and another known anticancer drug such as Paclitaxel, Doxorubicin, Mitomycin C and the like; Trans-Resveratrol [(E)- 3,4',5-trihydroxystilbene) and another known anticancer drug such as Paclitaxel,
- Doxorubicin Mitomycin C and the like; Retinoic acid (including all trans-retinoic acid) and Butyric acid. Paclitaxel and Captopril, Doxorubicin and Biotin. 5-Fluorouracil and
- Cytarabine Edatrexate and Paclitaxel; Cephalosporanic acid and Paclitaxel;
- Cephalosporin and Paclitaxel Cephalosporin and Paclitaxel; and Paclitaxel and Gemcitabine, ANTIPERKINSON'S: Levodopa and Carbidopa.
- ANTIBIOTICS Amoxicillin and Clavulanic acid; Ampicillin and Clavulanic acid, Amoxicillin and Pencillinic acid sulfone; Ampicillin and Pencillinic acid sulfone; Olivanic acid (or any carbapenem antbiotic) and a renal dipeptidase (dehydropeptidase I) inhibitor such as 3-substituted Z-2-acylaminopropionic acid and the like.
- ANTILIPIDEMIC AND HYPERTENSION Lifibrol and
- Mometasone and Formoterol/Salmeterol Fluticasone and Formoterol/Salmeterol;
- Diclofenac any known NSAID
- Misoprostol Diclofenac (any known NSAID) and a proton pump inhibitor such as Omeprazole, Lansoprazol, Rabeprazole, Leminoprazole, Pantoprazole, and the like
- a known antibacterial agent and a proton pump inhibitor such as Omeprazole
- ANTIVIRAL HAV/AIDS, PEPATITIS B AND OTHER VIRAL INFECTIONS: Zidovudine and Lamivudine; Triple prodrug of Zidovudine; Lamivudine and Abacavir (Ziagen); Lopinavir and Ritonavir; Lamivudine and Adefovir or its prodrug adefovir dipivoxil; Amprenavir and Zidovudine; Nelfmavir and a nucleoside reverse transcriptase inhibitor such as Zidovudine, Lamivudine, and the like; Stavudine and an antiretroviral agent such as Zidovudine, Lamivudine, and the like; Dideoxyinosine and an antiretroviral agent such as Zidovudine, Lamivudine, and the like; Emtricitabine and Penciclovir/Famciclovir; Acyclovir (or any other known antiviral compound
- any selected pair of drugs can be in the form of nitrate ester (NO-releasing) prodrug(s) of formula (I) or pharmaceutically acceptable salts thereof and the other drug can be in its native form.
- NO-releasing prodrug form i.e., NO-Paracetamol and Ibuprofen/ Paracetamol and NO- Ibuprofen/ NO-Paracetamol and NO-Ibuprofen, etc.
- a pharmaceutical composition consisting of two or more of the above listed/qualified drugs, one of the drugs can be in the form of NO- releasing (nitrooxy derivative) prodrug and the other drug(s) in the combination can be in the form another type of prodrug(s).
- a pharmaceutical composition containing a combination of one of the above listed/qualified drug(s) and its own prodrug is also covered (i.e., a pharmaceutical composition consisting of NO-Paracetamol and Paracetamol in any proportion).
- the free drug will be useful for faster onset of action and the prodrug will be useful for extension of the duration of action as it releases the drug in a controlled fashion over a longer period of time.
- Such combination drug therapy may also minimize the toxicity and other side effects due to excessive plasma concentration of free drug.
- a pharmaceutical combination may contain a prodrug of one of the above listed/qualified drugs and an another type of prodrug of the same drug (i.e., NO prodrug of pracetamol and mutual prodrug of paracetamol with another drug) and these can be present in any therapeutic proportion depending on the medical need.
- DMF N,N-Dimethylformamide
- DSC N,N'-Disuccinimidyl carbonate
- CDI N,N'-Carbonyldiimidazole
- DCC N,N'-Dicyclohexylcarbodiimide EDAC.
- HCl l-Ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride
- HBTU O-(Benzotriazol- 1 -yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
- DIPEA N,N-Diisopropylethylamine
- PE Petroleum ether
- the prodrugs described herein can be prepared by any number of methods known/obvious to those skilled in the art.
- the synthetic approaches and the linkages are chosen depending upon the functional groups such as carboxyl, hydroxyl, amino or carbonyl groups present in the drug molecules to be used.
- the following illustrative methods, as shown in Schemes 1 through 9, can be utilized to make carbonate, urethane, amide, ester, N-acyl carbamate, N-acyl amide, N-acyl sulfamate, and N-acyl sulfonamide, N-acyl phosphoramide, N-oxycarbonylsulfonamide, N- oxycarbonylcarbamate linkages, etc., between drug(s) and linker(s).
- the carbonate linkage between the drug and the linker can be made by reacting the hydroxyl-containing drug (alternatively, hydroxyl group of the linker) with phosgene or its equivalents such as diphosgene, triphosgene, N,N'-carbonyldiimidazole (CDI), N,N'-disuccinimidyl carbonate (DSC), 4-nitrophenyl chloroformate and the like, to give a reactive alkoxycarbonyl derivative, where LG is suitable leaving group such as a halide, imidazole, O-succinimide, 4-nitrophenoxide and the like, which can be reacted with hydroxyl group of the linker (alternatively, hydroxyl group of drug if the linker is converted to active alkoxycarbonyl derivative) in the presence of a suitable base and solvent.
- phosgene or its equivalents such as diphosgene, triphosgene, N,N'-carbonyldiimidazole (
- Rx and Ry are any monovalent organic radicals
- urethane linkage(s) As shown in scheme 2, the urethane linkage between the drug and the linker can be made by reacting the hydroxyl-containing linker with phosgene or its equivalents (defined above) to give a reactive alkoxycarbonyl derivative, which can be reacted with amino-containing drug in the presence of a suitable base and solvent. Alternatively, a urethane linkage can be made by adding an alcohol to an isocyanate.
- an amide or ester linkage between the drug and the linker can be made by reacting a carboxyl-containing drug with an amino- or hydroxyl- containing linker in the presence of a suitable coupling agent, base and solvent.
- the carboxyl-containing compound can be first converted to reactive carbonyl derivative such as an acid halide, a succinimide ester, a pentafluorophenyl ester, an imidazolide and the like, which can be treated with amino-containing or hydroxyl- containing linker in the presence of a suitable base and solvent to afford the corresponding amide or ester linkage(s), respectively (see, Bodanszky, M. and
- Rx, Ry, and Rz are any monovalent organic radicals
- Suitable coupling agents include DCC, EDCLHCl, BOP, HBTU, TBTU, DCC/HOBT, EDC/HOBT, and the like.
- Suitable bases and solvents are same as defined above.
- the linkage such as N-acyl carbamate linkage between the linker and drug can be made as shown in Scheme 4.
- treatment of an alcohol with phosgene or its equivalent can yield the corresponding carbonochloridate, which upon treatment with ammonia gas can give the corresponding carbamate intermediate.
- the carbamate nitrogen can be acylated by a suitable carboxylic acid derivatives such as anhydride or acid halide, a succinimide ester, a pentafluorophenyl ester, an imidazolide, and the like, in the presence of a suitable base to yield the corresponding N-acyl carbamate.
- N-acyl carbamate can be made by the reaction of an alcohol with N-acyl isocyanate, which can be prepared either by the reaction of the corresponding amide with oxalyl chloride (See, Speziale, A. J. et al., J. Org. Chem. 1962, 27, 31 '42; Speziale, A. J. et al, J. Org. Chem. 1963, 28, 1805-1811) or by the reaction of the corresponding acid chloride with silver cyanate. (See, Hill, AJ. et. al., J. Am. Chem. Soc, 1940, 62, 1595; Kim, D.K. J. Heterocyclic Chem. 1995, 32, 1625).
- the N-acyl amide linkage between the linker and drug can be made as shown in Scheme 5.
- the amide nitrogen can be acylated by a suitable carboxylic acid derivatives such as anhydride or acid halide, a succinimide ester, a pentafluorophenyl ester, an imidazolide, and the • like, in the presence of a suitable base to yield the corresponding N-acyl amide.
- Rx and Ry are any monovalent organic radicals.
- the linkage such as N-acyl sulfamate between the linker and drug can be made as shown in Scheme 6.
- treatment of an alcohol with sulfuryl chloride in the presence of suitable base gives the intermediate sulfochloridate, which can be converted to the corresponding sulfamate.
- a suitable carboxylic acid derivatives such as anhydride or acid halide, a succinimide ester, a pentafluorophenyl ester, an imidazolide, and the like, can yield the corresponding N-acyl sulfamate.
- Rx and Ry are any monovalent organic radicals.
- N-acyl/oxycarbonyl sulfonamide linkage between the linker and drug can be made as shown in Scheme 7.
- a sulfonamide nitrogen can be acylated by a suitable
- carboxylic acid derivatives such as anhydride or acid halide, a succinimide ester, a pentafluorophenyl ester, an imidazolide, and the like, to yield the corresponding N- acylsulfonamide, which can me metallated using an inorganic base.
- the sulfonamide nitrogen can be acylated by a suitable formyl chloride derivative such as alkyloxycarbonyl chloride, imidazolide and the like, to yield the corresponding N- alkyloxycarbonyl sulfonamide as shown in the scheme.
- the same linkage can be made by the reaction of an alcohol with sulfonyl isocyanate which can be prepared by known methods such by treatment of sulfonamide with oxalyl chloride (see, Hans Krzikalla et al., US2666787 or Smith, J. et al., J. Org. Chem. 1965, 30, 1260-1262) or by treatment of sulfonyl chloride with silver cyanate (See, Smith, J. et al., J. Org. Chem. 1965, 30, 1260-1262).
- Rx, and Ry are any monovalent organic radicals; M is a metal ion; x is 1-4
- N-oxycarbonylcarbamate (or N-oxycarbonylurea) linkage between the linker and drug can be made as shown in Scheme 8.
- carbamate nitrogen can be acylated by suitable formyl chloride derivatives such as alkyloxycarbonyl chloride, imidazolide and the like, to yield the corresponding N-alkyloxycarbonylcarbamate as shown in the scheme.
- the N-oxycarbonylcarbamate (or N- oxycarbonylurea) linkage between the linker and drug can be made by the reaction of an alcohol (or an amine) with carbamoyl isocyanate (IP15A), which can be prepared by known methods such by treatment of carbamate with oxalyl chloride (See, Grehn L, et al, Synthesis, 1988, 922-994) or by treatment of a formyl chloride with silver cyanate (See, Kim, D.K. et al., J. Heterocyclic Chem. 1995, 32, 1625).
- N- oxycarbonylcarbamate (or N-oxycarbonylurea) can be prepared in two steps.
- Step 1 reaction of an alcohol or phenol with chlorocarbonyl isocyanate to give N-oxycarbonyl carbamoyl chloride intermediate (IP15B).
- Step 2 reaction of the intermediate IP15B with the same or another alcohol or phenol or an amine.
- X NRz Rx, Ry and Rz are any monovalent organic radicals.
- Nitrate CnitrooXyl or Nitrite (nitrosyloxy) esters are same as defined above.
- nitrate or nitrite esters can be made as shown in Scheme 9.
- a nitrate or nitrite ester can be made by treating an alcohol with HNO 3 ZH 2 SO 4 (or HNU 3 /Ac 2 O) or nitrosyl chloride, respectively.
- a nitrate ester can be made by treating a halide (bromide or iodide is preferred) with silver nitrate in a polar aprotic solvent such as acetonitrile.
- Rx is any monovalent organic redical.
- Suitable protecting groups include, but not limited to, acetyl, Boc, Fmoc, benzoyl, pivaloyl, trityl, tetrahydropyranyl (THP), and silyl (TBDMS, TMS, etc.). Obviously, selection of a suitable protecting group is very crucial for the success of a chosen method for the synthesis of prodrugs described in this invention.
- AMDx is a CONH 2 -containing drugs such as vapromide, levotiracetam, carbamazepine, and the like.
- SAMDx is a SO 2 NH 2 -containing drugs such as valdecoxib, celecoxib, and the like.
- Scheme 15 Synthesis of Water-soluble Prodrug(s) using a bio-cleavable linker(s) and spacer linker (s)
- O X is a bond, O or N; R-X 4 H is an
- X is a bond, O or N;
- X 2 -CH 2 X 3 CH 2 - one or more solubilizing groups such as
- R x H, alkyl, CO 2 H, CH 2 CO 2 H, etc.
- R x H, alkyl, CO 2 H, CH 2 CO 2 H, etc.
- Double/Mutual prodrugs described in this invention can be synthesized by any of the approaches depicted in Schemes 17 through 19.
- Scheme 17 Synthesis of Mutual Prodrug(s) using a bio-cleavable linker(s) and spacer linker (s)
- R 2 H, a bond, CH 2 CH 2 N(CH 3 ) 2 .
- HCl an Amino acid, or any molecule containing solubilizing groups such as carboxylic acid, sulphonic acid, hydroxyl, amino groups, polyethyleneglycol (PEG), a metal ion such a Na + , Ca 2+ , etc.
- Scheme 24 An alternative method for the synthesis of Linker Intermediates LI-2b and LI-5
- Step 1 Synthesis of 2-((2-bromoethyl)dithio)ethanol (LI-2a) and bis(2- bromoethyl)disulfide (LI-3a): These compounds can be synthesized via bromination of SL-I by a known bromination method.(For a suitable bromination method, see Fruniss, B. S.
- Method 1 To a solution of SL-I (15g, 97.4 mmol) in DMF (50 mL) was added PPh 3 (25.5g, 97.4 mmol) and cooled to 0 0 C. Bromine (3.33 mL, 64.9 mmol) was added drop- wise and stirred at RT for 18 h. TLC of the mixture showed the mono-bromo derivative LI-2a as the major product with only trace amounts of dibromide LI-3a. The mixture was diluted with water and extracted with EtOAc.
- Method 3 To a cold suspension of SL-I (20 g, 129 mmol) in DCM (400 mL) was added CBr 4 (42 g, 129 mmol) and stirred for 10 min. PPh 3 (34 g, 129 mmol) was then added and stirred at RT for 14 h. The reaction mixture was concentrated and the residue purified by column chromatography to give 13.5 g (52.3%) of LI-2a and 13.0 g (36%) of LI-3a. These compounds were identical (by TLC, NMR and MS) to those obtained in Methods 1 and 2 described above.
- the above linker intermediate can also be prepared by the following method: Step 1: TEA (37 ml, 264 mmol) and a solution of (Boc) 2 O (48 g, 220 mmol) in DCM (100 mL) were added to a suspension of cystamine dihydrochloride (20 g, 88.8 mmol) in of DCM (300 mL) and stirred at RT for 15 h.
- Step 2 A solution of 2-mercaptoethanol (1.44 g, 18.5 mmol) in DCM (10 mL) was added to a mixture of tert-butyl 2-( ⁇ 2-[(tert-butoxycarbonyl)amino]ethyl ⁇ dithio)ethyl carbamate (5.0 g, 14.2 mmol) and TEA (3.87 ml, 27.7 mmol) in DCM (30 mL) and stirred overnight at RT. After usual aqueous work-up and chromatographic purification, 2.0 g (56%) of LI-2c was obtained.
- linker intermediates LI-2b and LI-2c can also be synthesized by following the method outlined in Scheme 24.
- Example 7
- the above linker intermediate was also prepared by the following method: TEA (3.56 g, 35.2 mmol) was added to a solution of cysteamine hydrochloride (2g, 17.60 mmol) and LI-3b (4.29g, 17.6mmol) in methanol (25mL) at 0 0 C and stirred at RT for 4 h. To the mixture, which contained the intermediate free amine (LI-5), a solution of (BoC) 2 O (7.68 g, 35.2 mmol) and TEA (3.56 g, 35.2 mmol) in MeOH (1OmL) was added and the mixture was stirred overnight. The reaction mixture was filtered through celite and evaporated to dryness. The residue was purified by column chromatography to afford 0.380 g (7 %) of LI-2f.
- the above linker intermediate LI-5.TFA was also synthesized as described below: TEA (3.56 g, 35.2mmol) was added drop-wise to a solution of cysteamine hydrochloride (2g, 17.60mmol) and LI-3b (4.29g, 17.6mmol) in MeOH (25mL) at 0 0 C and stirred at RT for 4 h. The mixture was cooled to 0 0 C and a solution of (Boc) 2 O (7.68 g, 35.2mmol) in MeOH (10 mL) was added, followed by TEA (3.56 g, 35.2mmol), and stirred overnight at RT. The reaction mixture was filtered through celite and the filtrate concentrated.
- prodrug I-C1-PD10 This prodrug was synthesized as described in Scheme 11, Method B. Thus, TEA (0.73 mL, 10 mmol) was added to a suspension of cetirizine dihydrochloride (2.0 g, 4.68 mmol) in DCM (50 mL), followed by a solution of SL-I (0.72 g, 4.67 mmol), DCC (1.13 g, 5.47 mmol) and DMAP (0.112g, 1 mmol) and stirred at RT for 15 h. The mixture was concentrated and the residue, after usual aqueous work- up and chromatographic purification, gave 0.44 g (19%) of I-C1-PD10.
- Step 1 To a suspension of aspirin (3 g, 16.65 mmol) in benzene (25 mL) and DMF (2 drops) at 0-5 0 C was added oxalyl chloride (1.7 mL, 19.98 mmol) in benzene (5 mL). The reaction mixture was refluxed at 85 0 C for 2 h, cooled to RTe and concentrated to give a yellow oil.
- Step 2 The yellow oil was dissolved in benzene (30 mL), silver cyanate (2.99 g, 19.98 mmol) was added and the mixture was refluxed for Ih in the dark.
- Step 3 The reaction mixture was cooled to RT, and a solution of SL-I (2.56 g, 16.65 mmol) in benzene (5 mL). The reaction mixture was stirred for Ih, filtered through celite, concentrated and purified by column chromatography to afford 2.24 g (54%) of I-Cl- PD6.
- Example 14 Synthesis of prodrug I-Cl-PDll:To a solution of SL-I (7g, 45.45 mmol) and valproic acid (7.85 g, 54.5 mmol) in DCM (80 mL) was added DCC (11.26 g, 54.5 mmol), followed by DMAP (6.65 g, 54.5 mmol), and the resulting suspension was stirred at RT for 18 h. After usual aqueous work-up and chromatographic purification, 2.82 g (22 %) of I-C1-PD11 were obtained as a colorless oil.
- Example 21 Syntheis of prodrug I-A1-PD5: To a solution of diphosgene (0.99 mL, 8.24 mmol) in DCM (3 mL) at 0 0 C was added a solution of L3I2a (0.5 g, 2.74 mmol) and H ⁇ nig's base (2.39 mL, 13.73 mmol) in DCM (3 mL). The mixture was stirred at 0 0 C for 30 min and concentrated to yield the intermediate L3I3a as a light-yellow semi-solid.
- Example 22 Synthesis of prodrug I-A1-PD6: To a solution of I-A1-PD8 (1.0 g, 2.63 mmol) in DCM (3 mL) at RT was added CDI (0.46 g, 2.89 mmol) and stirred for 15 h. A suspension of serine methyl ester hydrochloride (0.61 g, 3.95 mmol) in DCM (4 mL) and TEA (1.1 mL, 7.90 mmol) was added and stirring continued for 15 h. After usual aqueous work-up and chromatographic purification, 0.706 g (51%) of I-A1-PD6 were obtained as a colorless oil.
- Example 23 Synthesis of prodrug I-A1-PD7: To a solutuion of I-A1-PD8 (86 mg, 0.22 mmol) in DCM (9 mL) at RT was added CDI (40 mg, 0.24 mmol) and stirred for 15 h, after which a solution of dimethyl glutamate (80 mg, 0.45 mmol) and TEA (0.06 mL, 0.45 mmol) was added and stirred for 2 d. After usual aqueous work-up and chromatographic purification, 97 mg (74 %) of I-A1-PD7 were obtained as a colourless oil.
- Example 24 Synthesis of prodrug I-A1-PD9: To a suspension of gabapentin (10 g, 58.4 mmol) in THF (100 mL) at 0 0 C was added IN NaOH (70 mL), followed by (Boc) 2 O. The mixture was stirred at RT for 15 h. After washing with diethyl ether (100 mL x 2), the aqueous layer was acidified with solid KHSO 4 and extracted with EtOAc (100 mL x 2). Organic extracts were washed with brine (100 mL), dried over Na 2 SO 4 and concentrated to afford 10.41g (68 %) of boc-protected gabapentin as a white solid. A mixture of boc-protected gabapentin (5.0 g, 18.45 mmol) and CDI (3.59 g,
- Example 25 Synthesis of prodrug I-A1-PD10 : A mixture of I-A1-PD8 (1.Og, 2.63 mmol) and CDI (0.469 g, 2.89 mmol) in DMF (3 mL) was stirred for 12 h, after which N,N ' dimethylethylenediamine (0.56mL, 5.26 mmol) and DMAP (0.32 g, 2.63 mmol) was added. The mixture was stirred for 4 h. After usual aqueous work-up and chromatographic purification, 0.763 g (59 %) of were obtained as a yellow oil.
- Example 29 Synthesis of prodrug I-A1-PD12: To a solution of diphosgene (1.91 mL, 15.81 mmol) in DCM (20 mL) at 0 0 C was added a solution of I-A1-PD8 (4 g, 10.54 mmol) and H ⁇ nig's base (5.5 mL, 31.62 mmol) in DCM (30 mL). The mixture was stirred at RT for 40 min, cooled to 0-5 0 C, and dry ammonia gas was passed through it for 30 min. Reaction mixture was concentrated and, after usual aqueous work-up, 5.3 g (91 %) of I-A1-PD12 were obtained.
- prodrug I-A1-PD14 Ethyl chloroformate (0.86 g, 7.9 mmol) was added to a solution of S-carbamoylmethyl-S-methylhexanoic acid (M. S. Hoekstra et al., Org. Proc. Res. Dev. 1997, 1, 26-38) (1.0 g, 5.3 mmol) in THF (6 niL) at -10 0 C, followed by TEA (2.4 mL, 17.0 mmol) and the mixture was stirred at -10 0 C for 30 min. A solution of NaN 3 (1.73 g, 26.6 mmol) in water (10 mL) was added and stirred for 2h at -10 0 C.
- S-carbamoylmethyl-S-methylhexanoic acid M. S. Hoekstra et al., Org. Proc. Res. Dev. 1997, 1, 26-38
- Example 31 Synthesis of prodrug I-Al-PD15Ba: To a solution of I-A1-PD4 (0.350 g, 0.802 mmol) in DMF (3 mL) at RT was added CDI (0.195g, 1.204 mmol) and stirred at RT for 3 h. This mixture was added to a suspension of methanesulphonamide (0.304 g, 3.2 mmol) in DMF (4 mL) and NaH (0.153 g, 3.2 mmol) at 0 0 C and stirred at RT for 4 h.
- prodrug I-A2-PD1 To a solution of levetiracetam (1.0 g, 5.87 mmol) in DCE (20 mL) and DCM (4 mL) was added oxalyl chloride (0.61 mL, 7.05 mmol), and heated at 70 0 C for 8h. Reaction mixture was cooled and added to a solution of SL-I (1.81 g, 11.75 mmol) in DCM (15 mL) and stirred at RT overnight. After chromatographic purification, 1.13 g (41%) of I-A2-PD1 were obtained.
- Example 35 Synthesis of prodrugs I-A3-PD3a and I-A3-PD3b: Step 1: DSC (210 mg, 0.824 mmol) and TEA (0.230 mL, 1.64 mmol) were added to a solution of methyl [(2- hydroxy ethyl)dithio] acetate (lOOmg, 0.549 mmol) in acetonitrile (1 mL) at O 0 C and stirred at RT for 3h. The mixture was concentrated and the residue dissolved DCM. Usual aqueous work-up and chromatographic purification gave the crude intermediate.
- Step 2 TEA (24mg, 0.236 mmol) and DMAP (13 mg) were added to a mixture of valdecoxib (62mg, 0.195 mmol) and the product obtained from step 1 above in THF (1 mL) and stirred at RT for 3 d. The mixture was concentrated and the residue dissolved in EtOAc. After usual aqueous work-up and chromatographic purification, 53 mg (52%) of I-A3-PD3a obtained.
- Step 3 The above material was converted to the corresponding mono-, and/or di-sodium salt forms I-A3-PD3b by using standard methods.
- IM LiOH solution 28 mg in ImL water
- the mixture was concentrated, the residue diluted with water, acidified with IN HCl ( ⁇ 3 ml, pH ⁇ 3) and extracted with EtOAc. After usual aqueous work-up and chromatographic purification, 20 mg (13%) of product were obtained.
- Step 3 Synthesis of intermediate LI-10: A solution of LI-9 (1.02 g, 3.80 mmol) in acetonitrile (10 niL) was added to a cold solution of DSC (1.46 g, 5.70 mmol) in acetonitrile (50 mL) followed by TEA (1.58 ml, 11.40 mmol), and stirred overnight at RT. The mixture was concentrated and the residue was taken up in DCM. After usual aqueous work-up, 1.33 g (85%) of LI-10 were obtained.
- Step 4 Synthesis of I-A3-PD4: TEA (0.194 mL, 1.39 mmol) and DMAP (73 mg, 0.6 mmol) were added to a solution of LI-10 (1.33 g, 3.24 mmol) and valdecoxib (364 mg, 1.16 mmol) in THF (6 mL) and stirred at RT for 5 d. The mixture was concentrated and the residue was taken up in DCM. After usual aqueous work-up and chromatographic purification, 177 mg (12 %) of LI-10 were obtained.
- Step 2 Synthesis of prodrug intermediate I-S13-PD1: A mixture of valdecoxib (280 mg, 0.892 mmol), DMAP (56 mg, 0.5 mmol) and TEA (150 ⁇ L, 1.06 mmol) in THF (5 mL) was stirred at RT for 4.5 d. The mixture was concentrated and the residue dissolved in EtOAc. After usual aqueous work-up and chromatographic purification, 354 mg (54 %) of I-S13-PD1 were obtained.
- Step 3 Synthesis of intermediate I-A3-PD1: To a solution of I-S13-PD1 (215 mg, 0.292 mmol) and triisopropylsilane (60 ⁇ L) in 0.75 ml of DCM was added 20%TFA in DCM (0.5 mL) and stirred at RT for 90 min. The mixture was concentrated and the residue purified by column chromatography to give 65 mg (46%) of I-A3-PD1.
- Step 4 Synthesis of I-A3-PD5-Me-ester: CDI (40mg, 0.243 mmol) was added to a solution of I-A3-PD1 (lOOmg, 0.202 mmol) in DMF (0.5 mL) and stirred at RT for 2.5 h. To this were added a solution of dimethyl glutamate (53 mg, 0.303 mmol) in DMF (0.3 mL) and DMAP (37 mg, 0.303 mmol) and stirred overnight at RT.
- CDI 40mg, 0.243 mmol
- Step 5 Synthesis of prodrug I-A3-PD5: IN Lithium hydroxide (1.2 mL, 1.2 mmol) was added to a solution of I-A3-PD5-Me-ester (100 mg, 0.144 mmol) in THF (0.4 mL) at 0 0 C and the mixture allowed to attain ambient temperature. After 30 min, the mixture was concentrated and the residue diluted with water. Acidification with IN HCl, followed by extraction with EtOAc, usual aqueous work-up and chromatographic purification gave 26 mg (26%) of I-A3-PD5.
- prodrug I-H1-PD1 This prodrug was synthesized as shown in Scheme 14, Method B. Step 1: A solution of metronidazole (5.0 g, 29.22 mmol) and CDI (5.21 g, 32.2 mmol) in
- Step 2 A solution of the imidazolide of metronidazole (7.32 g) in DMF (30 mL) was
- Step 2 Synthesis of I-H1-PD5: To a solution of I-S14-PD1 in DCM (15 mL) were added triisopropylsilane (0.446 ml, 2.17 mmol), followed by 10% TFA in DCM (15 mL) and stirred at RT for 30 min. The mixture was concentrated and purified by column chromatography to afford 0.68 g (70%) of prodrug I-H1-PD5.
- Step 1 To a solution of diphosgene (0.35 mL, 2.93 mmol) in DCM (3mL) was added a solution of LI-Id (0.404 mg, 1.75 mmol), Hunig's base (0.765 mL, 4.39 mmol) and the resulting mixture was stirred at RT for 45 min. The mixture was concentrated, the residue dissolved in DCM (5 mL), cooled in an ice-bath and treated with a solution of paclitaxel (500 mg, 0.585 mmol), Hunig's base (0.765 mL, 4.39 mmol) and DMAP (cat.) in DCM (5 mL) over 5 min and the resulting mixture was stirred at RT for 2 h. The mixture was purified by column chromatography to give 519 mg (78%) of the protected intermediate
- Step 2 To an ice-cold solution of S22-I2 (60 mg, 0.0532 mmol) in MeOH (1 mL) was added 2 drops of methanol saturated with ammonia gas and the resulting mixture was stirred for 1 h. The reaction mixture was purified by column chromatography to give 38 mg (69%) of I-S22-PD1 as an off white solid.
- Example 43 Synthesis of prodrug I-S22-PD2: To a solution of I-S22-PD1 (38 mg, 0.0367 mmol) in acetonitrile (0.6 mL) was added succinic anhydride (5 mg, 0.044 mmol) and DMAP (cat.). The resulting mixture was stirred overnight at RT and purified by column chromatography to give 12 mg (29%) of prodrug I-S22-PD2 as an off white solid.
- Paclitaxel and its prodrug I-S22-PD2 (2 mg each) were suspended in 1 mL water or PBS-buffer (pH 7.4). The suspensions were sonicated for 15 min and centrifuged (13,000 g) for 10 min. The supernatant was analyzed using HPLC.
- Example 44 Synthesis of mutual prodrug of desloratidine and pseudoephedrine (I-AA-MPD1):
- Step 2 Synthesis of I-AA-MPD2: CDI (1.23 g, 7.64 mmol) was added to a solution of I-A1-PD2 (Example 18) (3.0 g, 5.09 mmol) in DMF (10 rxiL) and stirred RT for 3.5 h. A solution of lisinopril diethyl ester (2.34 g, 5.09 mmol) in DMF (5 niL) was added and stirred at 65 0 C for 8 h. The reaction was quenched with brine and taken up in EtOAc. After usual aqueous work-up and chromatographic purification, 2.5 g (45%) of I-AA- MPD2 were obtained.
- Step 1 A solution of SL-I (3.0 g, 19.4 mmol) in DMF (5 mL) was added to a suspension of CDI (9.46 g, 5.83 mmol) in DMF (15 mL) and stirred at RT for 20 h. The mixture was concentrated and the residue purified by column chromatography. The bis-imidazolide obtained was used as such in the next step.
- Step 2 A solution of the bis-imidazolide (1.0 g, 2.91 mmol) in acetonitrile (3 mL) was added to a dispersion of gabapentin (1.49 g, 8.75 mmol) in IN NaHCO 3 (8 mL) and stirred at RT for 3 d. The mixture was diluted with water, acidified with 2N HCl and extracted with EtOAc. After usual aqueous work-up and chromatographic purification, 1.04 g (65%) of pure I-AA-MPD10 was obtained.
- Example 56 Synthesis of mutual prodrug of gabapentin ethyl ester and levetiracetam (I-AA-MPD13): To a solution of levetiracetam (1.0 g, 5.87 mmol) in DCE (25 mL) and DCM (5 mL) at RT was added oxalyl chloride (895 mg, 7.05 mmol). The reaction mixture was refluxed for 8 h, after which it was cooled to RT and a solution of I-A1-PD8 (2.67 g, 7.05 mmol) in DCE (20 mL) was added drop-wise. The resulting mixture was stirred at RT for 18 h.
- Example 61 Synthesis of mutual prodrug of gabapentin ethyl ester and valproic acid (I-AA-MPD27): Step 1: To a solution of I-A1-PD8 (4.0 g, 10.54 mmol) in THF (25 mL) was added CDI (2.22g, 13.7 mmol) and stirred at RT for 90 min. To this was added t-butyl carbazate (1.39 g, 10.54 mmol) and DMAP (1.288 g, 10.54 mmol), and stirred overnight at RT.
- Step 2 To a solution of the above boc-hydrazide (4.0 g, 7.44 mmol) in DCM (20 mL) was added 50% TFA/DCM (10 mL) and stirred at RT for Ih. DCM was removed under vacuum, the resulting residue triturated with diethyl ether (2 x 20 mL) and dried to give a colorless oil, which was dissolved in THF (20 mL).
- Step 1 To a solution of nicotinyl chloride hydrochloride (3.16 g, 17.76 mmol) and LI-2c (3 g, 11.84 mmol) in THF (50 mL) was added TEA (8.3 mL, 59.2 mmol) and stirred overnight at RT. After usual aqueous work-up and chromatographic purification, 4.14. g (97%) of LI-2c-nicotinate ester was obtained as a colorless oil.
- Step 2 To a solution of LI-2c-nicotinate ester (0.92 g, 2.50 mmol) in DCM (5 mL) was added 50% TFA/DCM (5 mL) and stirred for Ih. Reaction mixture was concentrated and the residual TFA salt was used as such in Step 3.
- Step 3 To a solution of valproic acid (0.37 g, 2.56 mmol) in THF (5 mL) was added CDI (0.5 g, 3.08 mmol) and stirred for 2h. This was treated with a solution of the above TFA salt, TEA (0.7 mL, 5.13 mmol) and DMAP (50 mg, 0.41 mmol) in THF (10 mL) and the mixture was stirred overnight at RT. After usual aqueous work-up and chromatographic purification, 0.7 g (71%) of I-CC-MPD1 was obtained as a white solid.
- Step 2 Synthesis of I-HH-MPD1: Lamivudine (45 mg, 0.196 mmol) and DMAP (48 mg, 0.39 mmol) were added to a solution of I-S17-PDI1 (80 mg, 0.13 mmol) in DMF (1.5 mL) and stirred at RT for 30 min. The mixture was concentrated and purified by column chromatography to give 40 mg (43%) of product I-HH-MPD1.
- Step 2 The mutual prodrug I-C A-MPDl was synthesized by reacting intermediate I- S17-PDI1 with pseudoephidrine by a procedure similar to that described in Example 64, Step 2.
- the desired mutual prodrug I-CA-MPD1 was obtained as a colorless gummy , material.
- Step 2 Synthesis of I-AH-MPD1: A solution of the imidazolide of I-H1-PD1 (100 mg, 0.224 mmol) in DMF (1 mL) was added to a suspension of norfloxacin (86 mg, 0.269 mmol) in DMF (2 mL) and stirred at RT for 60 h. The mixture was concentrated and the residue purified by column chromatography to give 35 mg (22%) of I- AH-MPDl.
- Example 78 The following mutual prodrugs (Examples 78 - 80) were obtained according to procedures similar to those described in Example 77, with the substitution of the appropriate pairs of amino-containing and hydroxyl-containing therapeutic agents: Example 78
- Example 80 Synthesis of mutual prodrug of venlafaxine and paroxetine (I-AH-MPD8) The mutual prodrug was synthesized according to the method outlined in Scheme 15 with obvious modifications. The mutual prodrug I-AH-MPD8 was obtained as a white sticky solid. 1 H-NMR was consistent with the expected structure. MS: m/z 812 [M] + . Example 81
- This prodrug was synthesized as shown in Scheme 11, Method D.
- oxalyl chloride (1.86 mL, 21.64 mmol) and heated at 70 0 C for 2 h.
- the mixture was concentrated, the residue was dissolved in THF (30 mL) and treated with a solution of LI-2a (3.61 g, 16.65 mmol), TEA (3.48 mL, 24.97 mmol) and DMAP (361 mg) in THF (20 mL).
- the resulting mixture was stirred at RT for 2 h and filtered through celite.
- Step 1 To a suspension of aspirin (1 g, 5.55 mmol) in benzene (15 mL) and DMF (1 drop) at 0-5 0 C was added a solution of oxalyl chloride (0.6 mL, 6.66 mmol) in benzene (5 mL) and stirred at 85 0 C for 2 h. The reaction mixture was concentrated, and the crude acid chloride was used immediately in the next step.
- Step 2 To a solution of the above acid chloride in benzene (30 mL) was added silver cyanate (998 mg, 6.66 mmol) and refluxed in the dark for 1 h. The mixture, containing 2- acetoxybenzoyl isocyanate, was cooled to RT and used in the next step.
- Step 3 To the above mixture was added a solution of LI-2b (1.33 g, 6.66 mmol) in benzene (5 mL) and stirred at RT for Ih. The mixture was filtered through celite and concentrated, and the residue was purified by column chromatography to afford 1.2 g (54%) of pure I-Cl-NOPD5a. 1 H-NMR data is consistent with the expected structure.
- reaction mixture was concentrated and, after usual aqueous work-up, 4.5 g of flurbiprofen amide was obtained as a white solid.
- oxalyl chloride (1.87g, 14.79mmol) at 0 0 C and refluxed for 16 h.
- Reaction mixture was cooled to RT and treated with LI-2b (2.45 g, 12.33 mmol) in DCE (1OmL) and stirred overnight. After usual aqueous work-up and chromatographic purification, 0.5 g of I-Cl-NOPD14a were obtained.
- Example 97 Synthesis of NO-releasing prodrug of ketoprofen (I-C1-NOPD19): This prodrug was synthesized as shown in Scheme 11, Method A according to the method described in Example 90, using as reagents ketoprofen (1.27 g, 5 mmol), CDI (1.21 g, 7.5 mmol) and LI-2b (1 g, 5 mmol). Yield: 0.6 g (51%).
- Example 102 Synthesis of NO-releasing prodrug of lamotrigine (I-Al-NOPD3a and I-Al-NOPD3b): This prodrug was synthesized as shown in Scheme 12, Method B. Thus, to a suspension of lamotrigine (1 g, 3.90 mmol) in toluene (20 mL) at 120 0 C was added drop-wise a solution of the imidazolide of LI-2b (1.4 g, 4.70 mmol) in THF (10 mL) and refluxed for 6 h. After usual aqueous work-up and chromatographic purification, 340 mg (20%) of I- Al-NOPD-3a/b was obtained. 1 H-NMR data is consistent with the expected structure. MS (ES) + m/z: 481 (M+H) + .
- Example 103 Synthesis of NO-releasing prodrug of lamotrigine (I-Al-NOPD3a and I-Al-NOPD3b): This prodrug was synth
- This prodrug was synthesized from celecoxib (6.62 g, 17.35 mmol) according to the procedure described in Example 109 (see Scheme 13, Method B). After usual workup, the crude product was purified by column chromatography to afford 1.55 g (15%) of prodrug I-A3-NOPD2a.
- Example 111 Synthesis of NO-releasing prodrug of paracetamol (I-H1-NOPD1): This prodrug was synthesized as shown in Scheme 14, Method B. Thus, to a solution of paracetamol (2.0 g, 13.24 mmol) in THF (20 mL) was added CDI (2.36 g, 14.57 mmol) and the mixture was stirred at RT for 3 h.
- Step 2 To a mixture of LI-5.TFA (2.68 mmol) and TEA (1.08 g, 10.72 mmol) in DCM (10 mL) at 0 0 C was added the imidazolide of metronidazole (0.78 g, 2.95 mmol) and stirred at RT for 48 h. The reaction mixture was quenched with water and extracted with DCM. After usual aqueous work-up and chromatographic purification, 50 mg (4.3%) of I-H1-NOPD6 was obtained.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Surgery (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05781464A EP1789091B1 (en) | 2004-08-26 | 2005-08-26 | Prodrugs containing novel bio-cleavable linkers |
MX2007002210A MX2007002210A (en) | 2004-08-26 | 2005-08-26 | Prodrugs containing novel bio-cleavable linkers. |
DE602005023185T DE602005023185D1 (en) | 2004-08-26 | 2005-08-26 | PRODRUGS WITH NEW BIOSPIGBLE CONNECTORS |
BRPI0515218-6A BRPI0515218A (en) | 2004-08-26 | 2005-08-26 | compound, pharmaceutical composition, method for the treatment of a mammal or human, method of using the compound, new intermediates, use of the new intermediates, process for the preparation of a compound |
JP2007529100A JP5198063B2 (en) | 2004-08-26 | 2005-08-26 | Novel biocleavable linker |
CA002577490A CA2577490A1 (en) | 2004-08-26 | 2005-08-26 | Prodrugs containing alkyldisulfide linker groups |
NZ552539A NZ552539A (en) | 2004-08-26 | 2005-08-26 | Drug conjugates selected from cetrizine, desloratidine, terfenadine, fexofenadine or pseudoephedrine linked through a cleavable disulphide linker |
AU2005281359A AU2005281359A1 (en) | 2004-08-26 | 2005-08-26 | Prodrugs and codrugs containing novel bio-cleavable disulfide linkers |
AT05781464T ATE478685T1 (en) | 2004-08-26 | 2005-08-26 | PRODRUGS WITH NEW BIOcleavable Compounds |
IL181504A IL181504A0 (en) | 2004-08-26 | 2007-02-22 | Prodrugs containing novel bio-cleavable linkers |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60463204P | 2004-08-26 | 2004-08-26 | |
US60/604,632 | 2004-08-26 | ||
IN779/MUM/2005 | 2005-07-01 | ||
IN779MU2005 | 2005-07-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006027711A2 true WO2006027711A2 (en) | 2006-03-16 |
WO2006027711A3 WO2006027711A3 (en) | 2007-03-15 |
Family
ID=35695532
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2005/052797 WO2006027711A2 (en) | 2004-08-26 | 2005-08-26 | Prodrugs and codrugs containing bio- cleavable disulfide linkers |
Country Status (11)
Country | Link |
---|---|
EP (3) | EP1789091B1 (en) |
JP (2) | JP5198063B2 (en) |
KR (1) | KR20070053214A (en) |
AR (1) | AR054181A1 (en) |
AU (1) | AU2005281359A1 (en) |
BR (1) | BRPI0515218A (en) |
CA (1) | CA2577490A1 (en) |
IL (1) | IL181504A0 (en) |
MX (1) | MX2007002210A (en) |
RU (1) | RU2007110846A (en) |
WO (1) | WO2006027711A2 (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008010222A2 (en) * | 2006-07-17 | 2008-01-24 | Ramot At Tel Aviv University Ltd. | Conjugates comprising a gaba- or glycine compound, pharmaceutical compositions and combinations thereof and their use in treating cns disorders |
WO2009054682A2 (en) * | 2007-10-23 | 2009-04-30 | Astech Co., Ltd. | Prodrug of atrovastatin by cholesterol's synthesis inhibitors |
US7598239B2 (en) | 2001-09-27 | 2009-10-06 | Ramot At Tel Aviv University Ltd. | Conjugated psychotropic drugs and uses thereof |
WO2010012466A1 (en) * | 2008-08-01 | 2010-02-04 | Ganial Immunoterapeutics Inc. | Antitumor properties of no modified protease inhibitors |
WO2009129305A3 (en) * | 2008-04-15 | 2010-03-18 | Tsrl, Inc. | Prodrugs of neuraminidase inhibitors |
WO2010132691A1 (en) * | 2009-05-13 | 2010-11-18 | Nektar Therapeutics | Oligomer-containing substituted aromatic triazine compounds |
US8207369B2 (en) | 2008-02-11 | 2012-06-26 | Ramot At Tel-Aviv University Ltd. | Conjugates for treating neurodegenerative diseases and disorders |
WO2015095953A1 (en) | 2013-12-27 | 2015-07-02 | The Centre For Drug Research And Development | Sulfonamide-containing linkage systems for drug conjugates |
CN106459162A (en) * | 2013-12-27 | 2017-02-22 | 酵活有限公司 | VAR2CSA-drug conjugates |
US9636421B2 (en) | 2014-10-03 | 2017-05-02 | Synaffix B.V. | Sulfamide linker, conjugates thereof, and methods of preparation |
US9708628B2 (en) | 2011-11-18 | 2017-07-18 | Nof Corporation | Cationic lipid having improved intracellular kinetics |
US9879086B2 (en) | 2014-09-17 | 2018-01-30 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
WO2018127927A1 (en) * | 2017-01-09 | 2018-07-12 | Aposense Ltd. | Compounds and methods for trans-membrane delivery of molecules |
WO2018169934A1 (en) * | 2017-03-14 | 2018-09-20 | The Children's Hospital Of Philadelphia | Cleavable esters for nanocarrier-based cancer therapy |
CN108926718A (en) * | 2017-05-25 | 2018-12-04 | 烟台药物研究所 | A kind of amphiphilic polymer prodrug and its preparation method and application of reduction response release raw medicine |
US10201614B2 (en) | 2013-03-15 | 2019-02-12 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
US10517958B2 (en) | 2016-10-04 | 2019-12-31 | Zymeworks Inc. | Compositions and methods for the treatment of platinum-drug resistant cancer |
EP3638248A4 (en) * | 2017-06-16 | 2021-06-30 | The Regents of The University of California | Conjugates of active pharmaceutical ingredients |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2509603A1 (en) | 2009-12-09 | 2012-10-17 | Biolinerx Ltd. | Methods of improving cognitive functions |
RU2462254C2 (en) * | 2010-09-09 | 2012-09-27 | Федеральное государственное бюджетное учреждение науки Иркутский институт химии им. А.Е. Фаворского Сибирского отделения РАН | Silver nanocomposite of sulphated arabinogalactan exhibiting antimicrobial and antithrombotic activity and method for preparing it |
WO2012038963A1 (en) | 2010-09-22 | 2012-03-29 | Ramot At Tel-Aviv University Ltd. | An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same |
JP6013364B2 (en) * | 2010-12-23 | 2016-10-25 | アルカーメス ファーマ アイルランド リミテッド | Multiple API loading prodrug |
CN109608436B (en) * | 2011-04-08 | 2022-10-11 | 斯法尔制药私人有限公司 | Substituted methyl formyl reagents and methods of using same to improve physicochemical and/or pharmacokinetic properties of compounds |
JP6171014B2 (en) * | 2012-08-21 | 2017-07-26 | ヤンセン ファーマシューティカ エヌ.ベー. | Olanzapine hapten |
JP6762094B2 (en) * | 2013-02-28 | 2020-09-30 | タフツ ユニバーシティー | Disulfide compounds for drug delivery |
EA035190B1 (en) | 2014-06-02 | 2020-05-12 | Кетоген Инк. | Compounds for the treatment of seizures and other central nervous system disorders and conditions |
US10456405B2 (en) | 2015-09-07 | 2019-10-29 | Zhejiang Huahai Pharmaceutical Co., Ltd | Nitric oxide-releasing prodrug molecule of substituted quinazolines |
JP6889466B2 (en) * | 2016-12-09 | 2021-06-18 | 学校法人 名城大学 | A salt of an isolated compound containing an amide group, a method for producing the salt, and a method for synthesizing an amide compound using the salt. |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2666787A (en) | 1949-08-20 | 1954-01-19 | Basf Ag | Production of sulfonyl-isocyanates |
EP0214303A4 (en) * | 1985-02-22 | 1989-10-12 | Kyowa Hakko Kogyo Kk | Disulfide compounds and antineoplastic agents. |
US4952394A (en) * | 1987-11-23 | 1990-08-28 | Bristol-Myers Company | Drug-monoclonal antibody conjugates |
CA2026147C (en) * | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
IT1256450B (en) | 1992-11-26 | 1995-12-05 | Soldato Piero Del | NITRIC ESTERS WITH PHARMACOLOGICAL ACTIVITY AND PROCEDURE FOR THEIR PREPARATION |
US5571937A (en) * | 1994-05-13 | 1996-11-05 | Sloan-Kettering Institute For Cancer Research | Complementary DNA and toxins |
IT1276071B1 (en) | 1995-10-31 | 1997-10-24 | Nicox Ltd | ANTI-INFLAMMATORY ACTIVITY COMPOSITES |
US5807847A (en) | 1996-06-04 | 1998-09-15 | Queen's University At Kingston | Nitrate esters |
US6310052B1 (en) | 1996-06-04 | 2001-10-30 | Queen's University At Kingston | Nitrate esters and their use for neurological conditions |
US7115661B1 (en) | 1999-12-29 | 2006-10-03 | Queen's University At Kingston | Methods and compositions for mitigating pain |
IL120531A (en) | 1997-03-26 | 2006-12-31 | Yissum Res Dev Co | Nitric oxide donors and pharmaceutical compositions containing them |
US5767134A (en) | 1997-05-15 | 1998-06-16 | Vion Pharmaceuticals, Inc. | Prodrug forms of ribonucleotide reductase inhibitors 3-AP and 3-AMP |
US6169078B1 (en) * | 1998-05-12 | 2001-01-02 | University Of Florida | Materials and methods for the intracellular delivery of substances |
US6897305B2 (en) * | 1998-06-08 | 2005-05-24 | Theravance, Inc. | Calcium channel drugs and uses |
EP1085846A2 (en) * | 1998-06-08 | 2001-03-28 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
CA2319153A1 (en) * | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Novel sodium channel drugs and uses |
US6204257B1 (en) * | 1998-08-07 | 2001-03-20 | Universtiy Of Kansas | Water soluble prodrugs of hindered alcohols |
IT1307928B1 (en) | 1999-01-26 | 2001-11-29 | Nicox Sa | METHOD OF SYNTHESIS OF NITROXYMETHYLPHENYL ESTERS OF ASPIRINE DERIVATIVES. |
IT1311924B1 (en) | 1999-04-13 | 2002-03-20 | Nicox Sa | PHARMACEUTICAL COMPOUNDS. |
ITMI991517A1 (en) | 1999-07-09 | 2001-01-09 | Nicox Sa | PROCEDURE FOR OBTAINING EXTERNAL NITROXYMETHYL FENYL OF SALICYLIC ACID DERIVATIVES |
IT1314184B1 (en) | 1999-08-12 | 2002-12-06 | Nicox Sa | PHARMACEUTICAL COMPOSITIONS FOR THE THERAPY OF STRESS-OXIDATIVE CONDITIONS |
EP1210121A2 (en) * | 1999-08-24 | 2002-06-05 | Cellgate Inc. | Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
IT1319202B1 (en) | 2000-10-12 | 2003-09-26 | Nicox Sa | DRUGS FOR INFLAMMATORY-BASED DISEASES. |
IT1319201B1 (en) | 2000-10-12 | 2003-09-26 | Nicox Sa | DRUGS FOR DIABETES. |
JP2002193796A (en) * | 2000-12-27 | 2002-07-10 | Ajinomoto Co Inc | Inhibitor to activation of inflammatory factor, usage thereof and new polysulfide derivative usable for the same |
ITMI20010985A1 (en) | 2001-05-15 | 2002-11-15 | Nicox Sa | DRUGS FOR ALZHEIMER DISEASE |
ITMI20011307A1 (en) | 2001-06-21 | 2002-12-21 | Nicox Sa | DRUGS FOR EPILEPSY |
ITMI20011308A1 (en) | 2001-06-21 | 2002-12-21 | Nicox Sa | DRUGS FOR CHRONIC PAIN |
JP2004537594A (en) * | 2001-08-07 | 2004-12-16 | サネシス ファーマシューティカルズ, インコーポレイテッド | Disulfide and thiosulfonate ligands, and libraries containing these ligands |
ITMI20011744A1 (en) | 2001-08-09 | 2003-02-09 | Nicox Sa | DRUGS FOR VASCULOPATHIES |
AUPR879601A0 (en) * | 2001-11-09 | 2001-12-06 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
WO2004039771A1 (en) * | 2001-11-15 | 2004-05-13 | Department Of Science And Technology | Diallyldisulphide compounds having antilipidemic and antioxidant activity |
IL161409A0 (en) * | 2001-11-21 | 2004-09-27 | Sunesis Pharmaceuticals Inc | Methods for ligand discovery |
AUPS127202A0 (en) * | 2002-03-20 | 2002-04-18 | Walter And Eliza Hall Institute Of Medical Research, The | Therapeutic ion channel blocking agents and methods of use thereof |
US6756397B2 (en) * | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
ITMI20020773A1 (en) | 2002-04-11 | 2003-10-13 | Nicox Sa | DRUGS FOR THE TREATMENT OF ARTHRITIS |
ITMI20021399A1 (en) | 2002-06-25 | 2003-12-29 | Nicox Sa | CYCLOOXYGENASE INHIBITORS 2 |
ITMI20021391A1 (en) | 2002-06-25 | 2003-12-29 | Nicox Sa | NITRO-DERIVATIVES OF CYCLOOXYGENASE-2 INHIBITORS |
DK1592457T3 (en) * | 2003-01-27 | 2012-10-22 | Endocyte Inc | FOLATE-VINBLASTIN CONJUGATE AS MEDICINAL |
US7166638B2 (en) | 2003-05-27 | 2007-01-23 | Nicox S.A. | Statin derivatives |
US7169805B2 (en) | 2003-05-28 | 2007-01-30 | Nicox S.A. | Captopril derivatives |
RU2006100827A (en) | 2003-06-19 | 2007-07-27 | Никокс С.А. (Fr) | ENALAPRYL-NITRO-OXY DERIVATIVE DERIVATIVES AND RELATED COMPOUNDS AS ACE INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISEASES |
-
2005
- 2005-08-26 MX MX2007002210A patent/MX2007002210A/en unknown
- 2005-08-26 JP JP2007529100A patent/JP5198063B2/en not_active Expired - Fee Related
- 2005-08-26 WO PCT/IB2005/052797 patent/WO2006027711A2/en active Application Filing
- 2005-08-26 AR ARP050103578A patent/AR054181A1/en not_active Application Discontinuation
- 2005-08-26 RU RU2007110846/04A patent/RU2007110846A/en unknown
- 2005-08-26 BR BRPI0515218-6A patent/BRPI0515218A/en not_active IP Right Cessation
- 2005-08-26 AU AU2005281359A patent/AU2005281359A1/en not_active Abandoned
- 2005-08-26 EP EP05781464A patent/EP1789091B1/en not_active Not-in-force
- 2005-08-26 KR KR1020077002931A patent/KR20070053214A/en not_active Application Discontinuation
- 2005-08-26 EP EP10184535A patent/EP2266622A3/en not_active Withdrawn
- 2005-08-26 EP EP09157001A patent/EP2075011A3/en not_active Withdrawn
- 2005-08-26 CA CA002577490A patent/CA2577490A1/en not_active Abandoned
-
2007
- 2007-02-22 IL IL181504A patent/IL181504A0/en unknown
-
2012
- 2012-08-17 JP JP2012181087A patent/JP2013010773A/en active Pending
Non-Patent Citations (1)
Title |
---|
None |
Cited By (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7619006B2 (en) | 2001-09-27 | 2009-11-17 | Ramot At Tel Aviv University Ltd. | Conjugated psychotropic drugs and uses thereof |
US8168628B2 (en) | 2001-09-27 | 2012-05-01 | Ramot At Tel-Aviv University Ltd. | Conjugated psychotropic drugs and uses thereof |
US7939525B2 (en) | 2001-09-27 | 2011-05-10 | Bar-Ilan University | Conjugated psychotropic drugs and uses thereof |
US8283381B2 (en) | 2001-09-27 | 2012-10-09 | Ramot At Tel-Aviv University Ltd. | Conjugated psychotropic drugs and uses thereof |
US7598239B2 (en) | 2001-09-27 | 2009-10-06 | Ramot At Tel Aviv University Ltd. | Conjugated psychotropic drugs and uses thereof |
WO2008010222A2 (en) * | 2006-07-17 | 2008-01-24 | Ramot At Tel Aviv University Ltd. | Conjugates comprising a gaba- or glycine compound, pharmaceutical compositions and combinations thereof and their use in treating cns disorders |
US8377990B2 (en) | 2006-07-17 | 2013-02-19 | Ramot At Tel-Aviv University Ltd. | Conjugates comprising a psychotropic drug or a GABA agonist and an organic acid and their use in treating pain and other CNS disorders |
WO2008010222A3 (en) * | 2006-07-17 | 2008-04-10 | Univ Ramot | Conjugates comprising a gaba- or glycine compound, pharmaceutical compositions and combinations thereof and their use in treating cns disorders |
US8222296B2 (en) | 2006-07-17 | 2012-07-17 | Ramot At Tel-Aviv University Ltd. | Conjugates comprising a GABA- or glycine compound, pharmaceutical compositions and combinations thereof and their use in treating CNS disorders |
WO2009054682A3 (en) * | 2007-10-23 | 2009-06-11 | Astech Co Ltd | Prodrug of atrovastatin by cholesterol's synthesis inhibitors |
WO2009054682A2 (en) * | 2007-10-23 | 2009-04-30 | Astech Co., Ltd. | Prodrug of atrovastatin by cholesterol's synthesis inhibitors |
US8207369B2 (en) | 2008-02-11 | 2012-06-26 | Ramot At Tel-Aviv University Ltd. | Conjugates for treating neurodegenerative diseases and disorders |
WO2009129305A3 (en) * | 2008-04-15 | 2010-03-18 | Tsrl, Inc. | Prodrugs of neuraminidase inhibitors |
US9181281B2 (en) | 2008-04-15 | 2015-11-10 | SineVir Therapeutics LLC | Prodrugs of neuraminidase inhibitors |
WO2010012466A1 (en) * | 2008-08-01 | 2010-02-04 | Ganial Immunoterapeutics Inc. | Antitumor properties of no modified protease inhibitors |
US20110195939A1 (en) * | 2008-08-01 | 2011-08-11 | Ganial Immunotherapeutics Inc. | Antitumor properties of no modified protease inhibitors |
US8563578B2 (en) | 2008-08-01 | 2013-10-22 | Onconox Aps | Antitumor properties of NO modified protease inhibitors |
US8772479B2 (en) | 2009-05-13 | 2014-07-08 | Nektar Therapeutics | Oligomer-containing substituted aromatic triazine compounds |
US8895553B2 (en) | 2009-05-13 | 2014-11-25 | Nektar Therapeutics | Oligomer-containing substituted aromatic triazine compounds |
AU2010248943B2 (en) * | 2009-05-13 | 2015-05-21 | Nektar Therapeutics | Oligomer-containing substituted aromatic triazine compounds |
WO2010132691A1 (en) * | 2009-05-13 | 2010-11-18 | Nektar Therapeutics | Oligomer-containing substituted aromatic triazine compounds |
US9266845B2 (en) | 2009-05-13 | 2016-02-23 | Nektar Therapeutics | Oligomer-containing substituted aromatic triazine compounds |
KR101799113B1 (en) * | 2009-05-13 | 2017-11-17 | 넥타르 테라퓨틱스 | Oligomer-containing substituted aromatic triazine compounds |
US9617228B2 (en) | 2009-05-13 | 2017-04-11 | Nektar Therapeutics | Oligomer-containing substituted aromatic triazine compounds |
US9708628B2 (en) | 2011-11-18 | 2017-07-18 | Nof Corporation | Cationic lipid having improved intracellular kinetics |
US11617777B2 (en) | 2013-03-15 | 2023-04-04 | Zymeworks Bc Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
US10201614B2 (en) | 2013-03-15 | 2019-02-12 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
EP3087091A4 (en) * | 2013-12-27 | 2017-06-14 | Zymeworks Inc. | Var2csa-drug conjugates |
US11560422B2 (en) | 2013-12-27 | 2023-01-24 | Zymeworks Inc. | Sulfonamide-containing linkage systems for drug conjugates |
CN106459162A (en) * | 2013-12-27 | 2017-02-22 | 酵活有限公司 | VAR2CSA-drug conjugates |
US20170029490A1 (en) * | 2013-12-27 | 2017-02-02 | Zymeworks Inc. | Sulfonamide-containing linkage systems for drug conjugates |
WO2015095953A1 (en) | 2013-12-27 | 2015-07-02 | The Centre For Drug Research And Development | Sulfonamide-containing linkage systems for drug conjugates |
KR102384740B1 (en) | 2013-12-27 | 2022-04-07 | 자임워크스 인코포레이티드 | Sulfonamide-containing linkage systems for drug conjugates |
AU2014373640B2 (en) * | 2013-12-27 | 2018-08-30 | Var2 Pharmaceuticals Aps | VAR2CSA-drug conjugates |
RU2729194C2 (en) * | 2013-12-27 | 2020-08-05 | Займворкс Инк. | Sulfonamide-containing binding systems for medicinal conjugates |
AU2014373574B2 (en) * | 2013-12-27 | 2020-07-16 | Zymeworks Bc Inc. | Sulfonamide-containing linkage systems for drug conjugates |
KR20160124751A (en) * | 2013-12-27 | 2016-10-28 | 자임워크스 인코포레이티드 | Sulfonamide-containing linkage systems for drug conjugates |
US10675355B2 (en) | 2013-12-27 | 2020-06-09 | Var2 Pharmaceuticals Aps | VAR2CSA-drug conjugates |
RU2714933C2 (en) * | 2013-12-27 | 2020-02-21 | Займворкс Инк. | Var2csa-drug conjugates |
US10450378B2 (en) | 2014-09-17 | 2019-10-22 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
US10414822B2 (en) | 2014-09-17 | 2019-09-17 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
US9879086B2 (en) | 2014-09-17 | 2018-01-30 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
US11591405B2 (en) | 2014-09-17 | 2023-02-28 | Zymeworks Bc Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
US9636421B2 (en) | 2014-10-03 | 2017-05-02 | Synaffix B.V. | Sulfamide linker, conjugates thereof, and methods of preparation |
US11850286B2 (en) | 2014-10-03 | 2023-12-26 | Synaffix B.V. | Sulfamide linker, conjugates thereof, and methods of preparation |
US10792369B2 (en) | 2014-10-03 | 2020-10-06 | Synaffix B.V. | Sulfamide linker, conjugates thereof, and methods of preparation |
US10517958B2 (en) | 2016-10-04 | 2019-12-31 | Zymeworks Inc. | Compositions and methods for the treatment of platinum-drug resistant cancer |
US11230710B2 (en) | 2017-01-09 | 2022-01-25 | Aposense Ltd | Compounds and methods for trans-membrane delivery of molecules |
WO2018127927A1 (en) * | 2017-01-09 | 2018-07-12 | Aposense Ltd. | Compounds and methods for trans-membrane delivery of molecules |
WO2018169934A1 (en) * | 2017-03-14 | 2018-09-20 | The Children's Hospital Of Philadelphia | Cleavable esters for nanocarrier-based cancer therapy |
US11633485B2 (en) | 2017-03-14 | 2023-04-25 | The Children's Hospital Of Philadelphia | Cleavable esters for nanocarrier-based cancer therapy |
CN108926718B (en) * | 2017-05-25 | 2022-02-11 | 烟台药物研究所 | Amphiphilic polymer prodrug capable of releasing original drug in reduction response manner and preparation method and application thereof |
CN108926718A (en) * | 2017-05-25 | 2018-12-04 | 烟台药物研究所 | A kind of amphiphilic polymer prodrug and its preparation method and application of reduction response release raw medicine |
US11559585B2 (en) | 2017-06-16 | 2023-01-24 | The Regents Of The University Of California | Conjugates of active pharmaceutical ingredients |
AU2018283383B2 (en) * | 2017-06-16 | 2023-03-16 | The Regents Of The University Of California | Conjugates of active pharmaceutical ingredients |
EP3638248A4 (en) * | 2017-06-16 | 2021-06-30 | The Regents of The University of California | Conjugates of active pharmaceutical ingredients |
Also Published As
Publication number | Publication date |
---|---|
EP1789091B1 (en) | 2010-08-25 |
EP2075011A2 (en) | 2009-07-01 |
KR20070053214A (en) | 2007-05-23 |
EP2266622A2 (en) | 2010-12-29 |
RU2007110846A (en) | 2008-10-10 |
JP2013010773A (en) | 2013-01-17 |
CA2577490A1 (en) | 2006-03-16 |
MX2007002210A (en) | 2007-05-07 |
EP1789091A2 (en) | 2007-05-30 |
WO2006027711A3 (en) | 2007-03-15 |
EP2075011A3 (en) | 2012-02-29 |
AU2005281359A1 (en) | 2006-03-16 |
JP2008510795A (en) | 2008-04-10 |
JP5198063B2 (en) | 2013-05-15 |
IL181504A0 (en) | 2007-07-04 |
BRPI0515218A (en) | 2008-07-08 |
EP2266622A3 (en) | 2012-06-20 |
AR054181A1 (en) | 2007-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7932294B2 (en) | Prodrugs containing novel bio-cleavable linkers | |
WO2006027711A2 (en) | Prodrugs and codrugs containing bio- cleavable disulfide linkers | |
JP6290823B2 (en) | Biodegradable polymer-bioactive moiety complex | |
US20110263526A1 (en) | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | |
CN101039701A (en) | Prodrugs and codrusgs containing bio-cleavable disulfide linkers | |
US20150328323A1 (en) | Nitric Oxide Releasing Produgs of Therapeutic Agents | |
KR20060032994A (en) | Conjugated complement cascade inhibitors | |
US10709717B2 (en) | Polymer composed of repeat units having a biologically active molecule attached thereto via a pH-sensitive bond | |
US20230173092A1 (en) | Antibody-drug conjugates | |
US20220054649A1 (en) | Antibody-drug conjugates | |
WO2023047090A1 (en) | Antibody-drug conjugates | |
AU2012207022A1 (en) | Prodrugs containing novel bio-cleavable linkers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005281359 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 552539 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005781464 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077002931 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2005281359 Country of ref document: AU Date of ref document: 20050826 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005281359 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200701332 Country of ref document: ZA Ref document number: 2577490 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 181504 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/002210 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007529100 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2007110846 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 439/MUMNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580034555.7 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005781464 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0515218 Country of ref document: BR |